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Introduction
INTRODUCTION
Venous thrombosis is the result of excessive blood coagulation in veins, most 
frequently in the deep veins of the leg. The thrombus impairs or obstructs 
the blood ﬂow which leads to swelling of the affected limb, pain and red 
discoloration. Besides painful and disabling, venous thrombosis can be life-
threatening when part of the thrombus breaks off. Via the inferior caval vein 
the thrombus travels to the lungs where it may obstruct branches of the 
lung artery; a pulmonary embolism. Venous thrombosis occurs in about one 
in every 1000 persons per year 1. About two thirds of patients have deep 
vein thrombosis of the leg and one third has pulmonary embolism with or 
without concurrent deep vein thrombosis of the leg 1-3.
The traditional model for classiﬁcation of the pathology of venous thrombosis 
is known as ‘Virchow’s triad’, after the work by 19th century pathologist 
Rudolf Virchow 4,5. According to the triad, venous thrombosis occurs as a 
result of (1) alterations in blood ﬂow, (2) endothelial injury, or (3) alterations 
in blood constitution. Another classiﬁcation of causes is often made into (1) 
genetic causes and (2) acquired (or environmental) causes: some individuals 
have a strong genetic predisposition to develop venous thrombosis while 
others experience venous thrombosis only after environmental triggers such 
as long-term immobilization, oral contraceptive use or advanced age 6. In 
most cases, venous thrombosis presumably occurs after an environmental 
trigger on a background of increased susceptibility. Figure 1 (from 6) 
illustrates how these risk factors might relate to the occurrence of venous 
thrombosis in an individual. The factor V Leiden mutation here represents 
genetic predisposition, which remains constant during life. Depending on 
the genetic make-up of an individual, the “genetic predisposition level” will 
be higher or lower. Combined with increasing risk of venous thrombosis 
with advancing age and risk due to the presence of possible environmental 
triggers, an individual’s “thrombosis potential” might exceed the threshold 
for developing venous thrombosis.
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The search for genes involved in common diseases was facilitated by the rapid 
evolution of the ﬁeld of genetics in the last decade. With the completion of 
the Human Genome Project in 2003, a reference sequence of the 3 billion 
base pairs in the human genome has become publicly available (www.ornl.gov/
sci/techresources/Human_Genome/home.shtml). In 2002, The International 
HapMap Project was initiated with the goal to make a catalogue of genetic 
variation between individuals 8. The HapMap database, together with advances 
in genotyping technology, made it possible to perform genome-wide association 
studies for common diseases like type 2 diabetes 9-11 and breast cancer 12-14. 
A genome-wide association study measures genetic variants throughout the 
genome and links them to the occurrence of disease 15. 
A main source of genetic variation between individuals are single nucleotide 
polymorphisms (SNPs). In a SNP, two (for some SNPs three) allele options 
exist at one nucleotide position, for example an A-allele or a G-allele. The 
allele that is most prevalent in a population is called the major allele; the 
other is the minor allele. About 10 million “common” SNPs (minor allele 
frequency ≥0.01) exist in the human genome 16; on average one in every 300 
bases is a common SNP. SNPs that are located on the same chromosome are 
usually inherited together. This association between adjacent SNPs is known 
as linkage disequilibrium (LD), as opposed to the random combination 
(equilibrium) of different chromosomes during meiosis. Because of LD, it is 
possible to statistically predict the status of one SNP by genotyping a nearby 
SNP. SNPs that are genotyped to predict the status of other SNPs are known 
as “tag SNPs”. However, even for SNPs on the same chromosome, loss of 
LD occurs. During meiosis, two homologous chromosomes often exchange 
sections. This may result in recombination of DNA stretches of the two 
chromosomes, which decreases the degree of linkage between the nucleotides 
in a population. The larger the distance between two nucleotides, the higher 
the likelihood of recombination between the two positions and the lower the 
degree of LD. The principle of LD is the rationale for haplotype analysis, and 
the construction of the HapMap and similar databases. Knowledge of LD 
patterns in a population allows to efﬁciently capture variation in a genetic 
Figure 1: Models of thrombosis risk. In each panel, the ﬁgure shows the thrombosis (black) 
potential of each risk factor present during an individual’s life and the resultant thrombosis 
potential (red). (Reprinted from The Lancet 6)
Genetic risk factors are generally classiﬁed as ‘alterations in blood constitution’, 
although they could also involve the vessel wall or stasis. A range of pro- and 
anticoagulant proteins act in the process that leads to thrombus formation; 
genetic alterations in any of these proteins may alter their level or function. 
For example, deﬁciencies of the anticoagulant proteins antithrombin, protein 
C and protein S increase the risk of venous thrombosis, as do increased levels 
of the procoagulant proteins ﬁbrinogen, prothrombin, factor VIII, factor IX 
and factor XI 7. 
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Leiden Thrombophilia Study (LETS)
The LETS was designed to identify genetic risk factors for venous thrombosis. 
Four hundred seventy four patients with a ﬁrst venous thrombosis of the 
leg between January 1988 and December 1992 were recruited from the 
anticoagulation clinics of Leiden, Amsterdam and Rotterdam. Patients with 
malignant disorders, known to strongly increase the risk of venous thrombosis, 
were excluded. For each patient an unrelated control subject was recruited, 
matched on age and sex and having no history of venous thrombosis and no 
malignancy. Participants ﬁlled in a standard questionnaire on potential risk 
factors for venous thrombosis, and a blood sample was taken at least three 
months after discontinuation of anticoagulant therapy. Details of the LETS 
have been described previously 17,18.
Multiple Environmental en Genetic Assessment of risk factors for venous 
thrombosis (MEGA study)
The MEGA study was set up a decade after the LETS, and aimed to study 
combinations of genetic and environmental risk factors. The MEGA study 
included 4930 patients with a ﬁrst venous thrombosis of the leg or arm or 
pulmonary embolism who attended the anticoagulation clinics of Leiden, 
Amsterdam, Rotterdam, Den Haag, Utrecht or Amersfoort between March 
1999 and August 2004. Patients were asked to bring their partners as control 
subject. In addition, a population-based control group, frequency-matched to 
the patients on age and sex, was recruited by random digit dialing between 
January 2002 and December 2004. Overall 6287 control subjects were 
included in the MEGA study. Participants ﬁlled in a standard questionnaire 
on potential risk factors for venous thrombosis. A blood sample was taken at 
least three months after discontinuation of anticoagulant therapy from patients 
who were diagnosed before June 1, 2002, and their partners, and from the 
random population controls. Participants who refused to or were unable to 
provide a blood sample were offered the option of providing a buccal swab 
sample. Patients who were diagnosed from June 1, 2002, onwards and their 
partners received a cotton swab along with their questionnaire for collecting 
buccal cells. Details of the MEGA study have been described previously 19,20.
region by genotyping tag SNPs, instead of genotyping all known variants. 
These tag SNPs can be studied for association with disease.
Figure 2: From full nucleotide sequence to tag SNPs and haplotypes. From 5 individuals the 
full sequence of a stretch of DNA (e.g. part of a gene) is shown. Most of the DNA sequence 
is identical between these individuals, but some positions vary: the SNPs. For some of these 
SNPs the allele is predicted from other SNPs because of LD. For example, the three SNPs on 
the left only occur in combinations CAC or TTG. With the allele of one SNP the other two are 
known as well. SNPs 4, 6 and 7 are also in perfect LD; their alleles are predicted from com-
bining SNPs 5 and 8 (GG for the minor alleles, any other combination of SNP 5 and 8 for the 
major allele). A haplotype is the speciﬁc sequence of a DNA stretch and is identiﬁed by the tag 
SNPs. In the ﬁgure, each individual carries another haplotype.
STUDY POPULATIONS
Two case-control studies with similar design were used for the analysis of SNPs 
and the risk of venous thrombosis: the Leiden Thrombophilia Study and the 
Multiple Environmental and Genetic Assessment of risk factors for venous 
thrombosis. The Northwick Park Heart Study-II was used for the analysis of 
the F9 Malmö SNP and activation of coagulation factor IX in chapter 6.
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Introduction
to determine whether the association was due to linkage to another, more 
strongly associated and potentially causal SNP. The study also aimed to 
gain insight into the mechanistic aspect of the association. On one of the 
other SNPs from the SNP association study, we reported in more detail in 
Chapter 6. The SNP in the F9 gene, also known as F9 Malmö, was studied 
for linkage with nearby SNPs, and for association with coagulation factor IX 
levels (LETS and MEGA) and factor IX activation (NPHS-II).
Finally, in Chapter 7, we incorporated knowledge from previous and present 
research into a model that aims to predict the risk of venous thrombosis 
based on associated SNPs. We aimed to explore to what extent we can predict 
venous thrombosis using the currently known thrombosis-associated SNPs.
Northwick Park Heart Study-II (NPHS-II)
The NPHS-II is a cohort study of middle-aged men and was set up to study 
the association between coagulation and coronary heart disease. In total 
2951 men aged 50-61 years registered with nine general medical practices 
in England and Scotland were included in the study. Exclusion criteria were 
a history of unstable angina or myocardial infarction; regular anti-platelet 
or anticoagulant therapy; cerebrovascular disease; malignancy; conditions 
exposing staff to risk or precluding informed consent. Details of the NPHS-
II have been described previously 21.
OUTLINE OF THIS THESIS
The aim of the research presented in this thesis is to identify and evaluate 
common genetic variants that contribute to genetic susceptibility to venous 
thrombosis. We also studied the clinical importance of genetic variants in 
prediction of venous thrombosis.
Chapter 2 addresses the question whether the classical parameter to 
determine genetic predisposition, family history, remains of use now genetic 
predisposition can be measured at the molecular level.
In Chapter 3 the recent history of genetic research in venous thrombosis 
is summarized; it describes genetic variants that were identiﬁed in the last 
decade and aims to put the ﬁndings in perspective. One of the genetic variants 
of which its involvement in the etiology of venous thrombosis has been long 
debated is the MTHFR 677 C>T SNP. Chapter 4 describes the association 
between this SNP and venous thrombosis in the MEGA study.
Chapter 5 reports of a large-scale SNP association study in the LETS and 
MEGA studies. The study aimed to identify new genetic variants that 
contribute to the risk of venous thrombosis. Because the study design does 
not address the question of whether a single SNP association is causal, the 
chapter zooms in on the most strongly associated SNP in the CYP4V2 gene. 
In the region of this SNP, ﬁne-scale genotyping was performed in order 
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ABSTRACT 
Background A positive family history of venous thrombosis may reﬂect the 
presence of genetic risk factors. Once a risk factor has been identiﬁed, it is 
not known whether family history is of additional value in predicting an 
individual’s risk. We studied the contribution of family history to risk of 
venous thrombosis conditional on known risk factors.
Methods In the MEGA Study, a population-based case-control study, 
we collected blood samples and information about family history and 
environmental triggers from 1605 patients with a ﬁrst venous thrombosis 
and 2159 control subjects.
Results 505 (31%) Patients and 373 (17%) control subjects reported 
having one or more affected ﬁrst-degree relatives. A positive family history 
increased the risk of venous thrombosis more than twofold (odds ratio [95% 
conﬁdence interval], 2.2 [1.9-2.6]) and up to fourfold (3.9 [2.7-5.7]) when 
more than one relative was affected. Family history corresponded poorly 
with known genetic risk factors. Both in those with and without genetic 
or environmental risk factors, family history remained a risk indicator. The 
risk increased with the number of risk factors identiﬁed; for those with a 
genetic and environmental risk factor and a positive family history, the risk 
was about 64-fold the risk of those with no known risk factor and a negative 
family history. 
Conclusions Family history is a risk indicator for a ﬁrst venous thrombosis, 
regardless of the risk factors identiﬁed. In clinical practice the family history 
may be more useful for risk assessment than thrombophilia testing.
22
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INTRODUCTION
A positive family history of venous thrombosis may reﬂect the presence of genetic 
risk factors in a family. Carriers of a genetic risk factor are at increased risk of a ﬁrst 
venous thrombosis, particularly when exposed to environmental triggers. Factor 
V Leiden, for example, synergistically increases the risk of venous thrombosis 
in oral contraceptive users 22. Since universal screening is not cost-effective 23,24, 
research efforts are focused on selection criteria that may be used to increase the 
chance of ﬁnding a genetic risk factor. Family history is an evident candidate.
Several authors have studied the value of family history as a surrogate of known 
genetic risk factors for venous thrombosis 25-29. These studies have shown that 
the family history cannot be used to identify genetic risk factors because both 
positive predictive value and sensitivity are low.
Few have studied the association between family history and venous throm- 
bosis 30,31. In addition, it is not known whether family history is of additional 
value in predicting an individual’s risk of venous thrombosis once a genetic risk 
factor is identiﬁed. We therefore estimated the relative risk of venous thrombosis 
when the family history is positive and studied the contribution of family history 
to risk in strata of known risk factors. Family history was evaluated in patients 
with venous thrombosis and control subjects from the Multiple Environmental 
and Genetic Assessment of risk factors for venous thrombosis (MEGA study), a 
large population-based case-control study.
METHODS
Study Population and Data Collection
Recruitment, data collection and ascertainment of venous thrombosis events in 
the MEGA study were described in detail previously 20,32. Patients had experienced 
a ﬁrst deep vein thrombosis of the leg or pulmonary embolism between March 
1, 1999 and August 31, 2004. Control subjects were partners of patients or 
24
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years before or within six months after the index date. The index date was deﬁned 
as date of diagnosis for patients and their partners, and date of completing the 
questionnaire for random controls. 
Genetic risk factors
Genetic risk factors were the factor V Leiden mutation, the prothrombin 
20210A mutation, low antithrombin levels, low protein C levels and low protein 
S levels. Since many mutations in the genes encoding antithrombin, protein C 
and protein S may cause deﬁciency, protein levels served as a surrogate for genetic 
defects. A sample was classiﬁed as “low” when the protein level was below the 
reference value calculated in control subjects (geometric mean minus 2 standard 
deviations). For protein C and protein S, the reference values were calculated 
excluding vitamin K antagonist users. In addition, we compared protein C levels 
to factor VII levels, and protein S levels to factor II levels in order to discriminate 
between “isolated” low protein C or S levels and overall low coagulation factor 
levels. We calculated the expected protein C level by linear regression of protein 
C on factor VII, and calculated the observed over expected ratio for protein C 
34. For protein S the observed over expected ratio was calculated by regression on 
factor II. The observed protein C or S level was classiﬁed as “low” when both the 
absolute value and the observed over expected ratio were below the reference value 
calculated in control subjects (geometric mean minus 2 standard deviations). 
Speciﬁc reference values of protein C and protein S levels were calculated for 
vitamin K antagonist users that were included in sensitivity analyses; the ratios to 
factor VII and factor II are independent of vitamin K antagonist use.
For the present analysis we selected participants who provided complete 
information about family history and environmental triggers and donated a 
blood sample. Among 3033 patients who ﬁlled in the questionnaire, 2712 (89%) 
provided information about family history and of 1959 (65%) patients complete 
information about environmental triggers and a blood sample were available. In 
the control group, 4317 (88%) of 4887 participants provided information about 
family history and of 2438 (50%) control subjects complete information about 
environmental triggers and a blood sample were available.
random population control subjects. The random control subjects were recruited 
by random digit dialing 33 between January 1, 2002 and December 1, 2004, 
and frequency matched on sex and age to the patient group. All participants 
completed a questionnaire on risk factors for venous thrombosis and family 
history. A blood sample was taken three months after discontinuation of vitamin 
K antagonist therapy from patients who were diagnosed until June 1, 2002 and 
their partners. Patients with an indication for life-long treatment with vitamin K 
antagonists were invited for a blood draw one year after the index date. Patients 
who were diagnosed from June 1, 2002, onwards and their partners received a 
cotton swab along with their questionnaire for collecting buccal cells; these were 
not included in the present study. In the random population control group, blood 
samples were collected throughout the entire study period and after returning the 
questionnaire. Overall response rates were 83% in the patient group, 82% in the 
partner control group and 69% in the random population control group.
Family history
Participants were asked whether parents, brothers or sisters had experienced 
venous thrombosis and, if so, the age at the event. Because partners of patients 
were recruited as control subjects, offspring was not included in the family 
history deﬁnition. Family history was considered positive if at least one of these 
ﬁrst-degree relatives had experienced venous thrombosis. Within this group, 
participants with a strong indication of genetic predisposition were deﬁned as 
having at least one ﬁrst-degree relative affected before the age of 50 years, or 
having multiple ﬁrst-degree relatives affected regardless of their age. When none 
of the ﬁrst-degree relatives had suffered a venous thrombosis, family history was 
deﬁned negative. The answer ‘I don’t know’ was also considered negative.
Environmental triggers
Environmental triggers were surgery, injury (any self-reported injury, such as 
muscle ruptures or sprain), immobilization (plaster cast, extended bed rest at 
home for at least 4 days, hospitalization) and pregnancy or puerperium within 
three months prior to the index date, use of oral contraceptives or hormone 
replacement therapy at the index date and diagnosis of malignancy within ﬁve 
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of family history to identify genetic risk factors. For the positive predictive 
value and sensitivity estimates, binomial 95% CIs were calculated using the 
normal approximation.
RESULTS
Table 1. Distribution of age, sex and individual risk factors among patients with venous 
thrombosis and control subjects
Patients (N=1605) Control Subjects (N=2159)
Median age (5th – 95th percentile) 50 (27-68) 51 (28-67)
Men, N (%) 772 (48%) 1150 (53%)
Type of VTE, N (%)
DVT 949 (59%) NA
PE 510 (32%) NA
DVT & PE 191 (9%) NA
Environmental Risk Factor, Any, N (%) 1086 (68%) 425 (20%)
Surgery 276 (17%) 63 (3%)
Injury 266 (17%) 141 (7%)
Immobilisation 496 (31%) 136 (6%)
Pregnancy/puerperium* 68 (4%) 21 (1%)
Oral contraceptives / HRT* 456 (29%) 108 (5%)
Malignancy 100 (6%) 48 (2%)
Genetic Risk Factor, Any, N (%) 393 (25%) 243 (11%)
Factor V Leiden mutation 246 (15%) 102 (5%)
Prothrombin 20210A mutation 73 (5%) 37 (2%)
Low antithrombin 39 (2%) 56 (3%)
Low protein C 35 (2%) 23 (1%)
Low protein S 26 (2%) 36 (2%)
NA=not applicable
*  The pregnancy and hormone use risk factor groups included women only, but the percen-
tages are of the total study group including men and women.
During pregnancy and oral contraceptive use protein S levels are reduced 
and cannot be used as an indicator of a genetic defect of protein S. We 
therefore excluded women who were pregnant (0 participants) or used oral 
contraceptives (146 patients and 259 control subjects) at the time of the 
blood draw. We also excluded vitamin K antagonist users (208 patients and 
20 control subjects) because protein C and protein S levels cannot be easily 
interpreted under these circumstances. After these exclusions 1605 patients 
and 2159 control subjects remained in the analyses.
Laboratory Analysis
Collection and processing of blood samples, subsequent DNA isolation and 
genotyping of factor V Leiden and the prothrombin 20210A mutation have 
been described previously 19. Measurements of antithrombin and protein 
C levels were performed with a chromogenic assay and factor II and VII 
level measurements were based on a mechanical clotting time assay. These 
measurements were performed on a STA-R coagulation analyzer following 
the instructions of the manufacturer (Diagnostica Stago, Asnières, France). 
Total protein S levels were measured by an enzyme-linked immunosorbent 
assay (ELISA, Diagnostica Stago, Asnières, France). The mean intra- and 
inter-assay coefﬁcients of variation were 1.7% and 2.6%, respectively, for 
antithrombin, 1.4% and 3.5% for protein C, 2.7% and 4.2% for factor II, 
3.4% and 4.0% for factor VII and 5.0% and 3.5% for protein S.
Statistical Analysis
Odds ratios (OR) and 95% conﬁdence intervals (CI) were computed to 
estimate the relative risk of venous thrombosis associated with a positive 
family history. Taking the group with a negative family history as reference, 
ORs were calculated for having any affected ﬁrst-degree relative (with the 
exception of offspring), having a ﬁrst-degree relative affected before the age 
of 50 years, and having multiple affected ﬁrst-degree relatives. Adjustment 
for age (continuous) and sex was performed by logistic regression. Subgroup 
analyses were performed within strata of known risk factors and within 10-
year age categories. We calculated the positive predictive value and sensitivity 
28
Chapter 2
29
C
ha
pt
er
 2
Family history of VT
the accuracy of family history to identify genetic risk factors, had an area 
under the curve of only 54% in patients and 53% in the control group. 
When we took the presence of a genetic risk factor as the starting point, a 
positive family history was reported by 38% of patient carriers and by 22% 
of control carriers (sensitivity, Table 3). Thus, the majority of thrombophilic 
carriers did not have affected relatives.
Table 3. Family history and prevalence of genetic risk factors in patients and control subjects
Study Group Family history a Known genetic  
risk factor b
Predictive value
(95% CI)
Sensitivity
(95% CI)
yes no
Patients Negative 243 857 78% (75% - 80%) NA
positive, any relative 150 355 30% (26% - 34%) 38% (33% - 43%)
positive, relative < 50 80 160 33% (27% - 39%) 20% (15% - 26%)
positive, > 1 relative 35 62 36% (27% - 46%) 9% (4% - 14%)
Control Subjects Negative 190 1596 89% (88% - 91%) NA
positive, any relative 53 320 14% (11% - 18%) 22% (17% - 27%)
positive, relative < 50 19 125 13% (8% - 19%) 8% (2% - 14%)
positive, > 1 relative 9 31 23% (10% - 35%) 4% (-3% - 11%)
a   History of venous thrombosis among parents, brothers and sisters
b  Low protein levels of antithrombin, protein C or protein S, factor V Leiden mutation, 
 prothrombin 20210A mutation
In order to study the value of family history as a risk indicator when known 
risk factors have been measured, we grouped patients and control subjects 
according to type of risk factor identiﬁed: none, environmental, genetic 
or both (Table 4). In all strata, patients more frequently reported to have 
affected relatives than control subjects. So, family history is a risk indicator 
regardless of the presence of known risk factors.
The relative risk associated with a positive family history was of similar 
magnitude as the risk associated with a genetic risk factor. In the absence 
of environmental triggers the ORs were 2.5 for family history and 2.3 for a 
Median age and distributions of sex and individual risk factors among the 
1605 patients and 2159 control subjects are listed in Table 1. Family history 
of venous thrombosis was positive for 505 (31%) patients and 373 (17%) 
control subjects (Table 2). The overall OR of a positive relative to a negative 
family history was 2.2 (95% CI, 1.9-2.6). The association was stronger when 
only family members with venous thrombosis before the age of 50 years were 
considered positive (OR, 2.7; 95% CI 2.2-3.4) or when several relatives 
were affected (OR, 3.9; 95% CI 2.7-5.7). The OR for venous thrombosis 
when having several relatives affected and at least one of them before the 
age of 50 was 4.4 (95% CI 2.8-6.9, not shown). The median (25th to 75th 
percentile) number of relatives, i.e. parents and siblings, that was reported in 
the questionnaire was 5 (3 to 7) in the patient group and 5 (3 to 6) in the 
control group.
Table 2. Distribution of ﬁrst-degree family history among 1605 patients with venous throm-
bosis and 2159 control subjects
Family history Patients, N (%) Control Subjects, N (%) OR (95% CI)
negative 1100 (69%) 1786 (83%) 1 [Reference]
Positive, any relative 505 (31%) 373 (17%) 2.2 (1.9 -2.6)
Positive, relative < 50 240 (15%) 144 (7%) 2.7 (2.2 -3.4)
Positive, > 1 relative 97 (6%) 40 (2%) 3.9 (2.7 -5.7)
In 150 of 505 (30%) patients with a positive family history a genetic risk 
factor was identiﬁed. A higher number of affected relatives and a younger 
age at which the relative was affected increased the chance to ﬁnd a genetic 
risk factor, up to 36% for patients with several affected relatives (positive 
predictive value, Table 3). The negative predictive value, i.e. the chance 
that known genetic risk factors are indeed absent when the family history is 
negative, was 78%. This indicates that 22% of patients were thrombophilic 
carriers despite a negative family history. In the control group genetic risk 
factors were less prevalent than among patients and the positive predictive 
values were lower. The ROC-curve for any relative affected, which represents 
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genetic risk factor. In the presence of environmental triggers the ORs were 
16.4 for family history and 21.2 for a genetic risk factor. The OR increased 
with the number of risk factors identiﬁed; for those with a combination of 
any genetic and acquired risk factor the risk was about 60-fold the risk of 
those with no known risk factor and a negative family history.
To rule out that the higher prevalence of positive family histories in patients 
with genetic risk factors was the result of speciﬁc combinations or the 
number of genetic risk factors, we stratiﬁed this group by the speciﬁc genetic 
risk factors. In the group that carried factor V Leiden but no other genetic 
risk factor (40 patients and 22 control subjects), a positive family history 
further increased the risk of venous thrombosis; factor V Leiden carriers with 
a positive family history had a 2.9 fold (95% CI 1.5-5.7) higher risk than 
factor V Leiden carriers with a negative family history. When an affected 
relative was younger than 50 years, this OR was 5.4 (95% CI 2.0-14.6) and 
when at least two relatives were affected 17.8 (95% CI 2.2-143.1). The other 
strata of speciﬁc genetic risk factors included fewer patients and control 
subjects thereby precluding meaningful analysis.
Table 4. Family history in strata of known risk factors.
Risk factor Family history a Patients Control 
Subjects
OR (95% CI) b OR (95% CI) c
No known risk factor
negative 261 (67%) 1286 (84%) 1 [Reference] 1 [Reference]
positive, any relative 128 (33%) 252 (16%) 2.5 (1.9 - 3.2) 2.5 (1.9 - 3.2)
positive, < 50 years 53 (14%) 98 (6%) 2.7(1.9 -3.8) 2.7 (1.9 - 3.8)
positive, 
multiple relatives
23 (6%) 27 (2%) 4.2 (2.4 - 7.4) 4.2 (2.4 - 7.4)
Environmental factor only d
negative 596 (72%) 310 (82%) 1 [Reference] 9.5 (7.8 - 11.5)
positive, any relative 227 (28%) 68 (18%) 1.7 (1.3 - 2.4) 16.4 (12.2 - 22.2)
positive, < 50 years 107 (13%) 27 (7%) 2.1 (1.3 - 3.2) 19.5 (12.5 - 30.4)
positive, 
multiple relatives
39 (5%) 4 (1%) 5.1 (1.8 - 14.3) 48.0 (17.0 - 135.6)
Genetic factor only e
negative 71 (55%) 150 (77%) 1 [Reference] 2.3 (1.7 - 3.2)
positive, any relative 59 (45%) 46 (23%) 2.7 (1.7 - 4.4) 6.3 (4.2 - 9.5)
positive, < 50 years 33 (25%) 15 (8%) 4.6 (2.4 - 9.1) 10.8 (5.8 - 20.2)
positive, 
multiple relatives
14 (11%) 6 (3%) 4.9 (1.8 - 13.4) 11.5 (4.4 - 30.2)
Environmental and genetic factor
negative 172 (65%) 40 (85%) 1 [Reference] 21.2 (14.7 - 30.6)
positive, any relative 91 (35%) 7 (15%) 3.0 (1.3 - 7.0) 64.1 (29.4 - 139.8)
positive, < 50 years 47 (18%) 4 (9%) 2.7 (0.9 - 8.0) 57.9 (20.7 - 162.1)
positive, 
multiple relatives
21 (8%) 3 (6%) 1.6 (0.5 - 5.7) 34.5 (10.2 - 116.5)
a History of venous thrombosis among parents, brothers and sisters
b Odds ratio per stratum of type of risk factors identiﬁed
c Odds ratio relative to the group with no known risk factor and a negative family history
d surgery, injury, immobilisation and pregnancy or puerperium within 3 months preceding 
 the index date, use of oral contraceptives or hormone replacement therapy at the index date 
 and diagnosis of malignancy within 5 years before or within six months after the index date
e Low protein levels of antithrombin, protein C or protein S, factor V Leiden mutation, pro- 
 thrombin 20210A mutation.
Genetic risk factors might play the most prominent role at young age, when 
environmental triggers are less prevalent. We therefore calculated ORs for 
family history per 10-year age category. Family history was associated with 
the risk of venous thrombosis in all age groups. The relative risk slightly 
decreased with age; the ORs (95% CIs) for any relative affected were 3.2 
(1.7-6.0) at age 18-29 years, 2.4 (1.6-3.6) at age 30-39 years, 2.1 (1.5-2.8) 
at age 40-49 years, 2.1 (1.6-2.8) at age 50-59 years and 2.2 (1.6-3.1) at age 
60-69 years. Because thrombotic events in a family accumulate during life 
and the risk of venous thrombosis increases with age, we further studied 
whether age could have confounded our results. Adjustment for age did not 
change any of the estimates. We also adjusted for sex to assess the impact of 
possible associations between oral contraceptive use and family history, but 
again none of the estimates changed.
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Relatives for whom the answer to the question about family history was 
‘I don’t know’ were assumed to be negative. Among patients, 238 of 1605 
(15%) had at least one relative with unknown venous thrombosis history 
while other relatives were negative (i.e. family history assumed negative), 
among controls 307 of 2159 (14%) answered ‘I don’t know’ for at least one 
relative. Excluding these participants from the analysis led to slightly higher 
risk estimates for the family history.
All analyses were repeated including vitamin K antagonist users and oral 
contraceptive users. Including these users inﬂuenced the family history 
distributions by only a few percent. 
COMMENT
In a large population-based case-control study we showed that a positive 
family history increased the risk of venous thrombosis more than twofold, 
regardless of the risk factors precipitating the thrombosis. A young age of 
the affected relative and in particular the number of affected relatives more 
strongly indicated a predisposition to develop venous thrombosis.
Family history and known genetic risk factors were poorly associated, as 
observed previously 25-27,29,35. Both the positive predictive value and sensitivity 
of family history as a test for genetic risk factors were low, with ROC-curves 
hardly different from a random distribution. The poor predictive value either 
implies the existence of unknown genetic risk factors or clustering through 
household effects.
Patients more frequently had a positive family history than control subjects, 
even when known risk factors were similar. This indicates that an unwknown, 
probably genetic factor has caused their disease in concert with the risk factor 
identiﬁed. These ﬁndings suggest that most genetic risk factors have low 
penetrance. Only when additional risk factors are present, venous thrombosis 
will develop 6,36. The search for novel genetic risk factors should not be 
limited to patients without known thrombophilia, since genetic factors that 
interact with already known genetic risk factors might then not be found. As 
most carriers of a single genetic risk factor have a negative family history, the 
sensitivity of family history to identify a single genetic risk factor is low.
We selected low levels of antithrombin, protein C and protein S, the factor 
V Leiden mutation and the prothrombin 20210A mutation as genetic risk 
factors. These are clear and frequent genetic risk factors for venous thrombosis. 
Inclusion of more genetic risk factors will increase the positive predictive 
value at the cost of the negative predictive value, while sensitivity may remain 
low. More important is that our study conﬁrms that venous thrombosis is a 
multi-gene disorder. Family history will be a better surrogate for multiple 
genetic risk factors, including those yet unknown, than for single defects.
Relatives generally underreport disease in their family 37-41. We believe that also 
in our study family history may have been underreported. It does, however, 
correspond to clinical practice where physicians rely on the family information 
given by their patient and conﬁrmation of all relatives’ disease status is not 
feasible. Alternatively, we might have overestimated the prevalence of positive 
family histories because individuals might be more prone to participate in a 
study when their family history is positive. As selection is most likely in the 
control group, we might have underestimated the effect of family history.
Antithrombin, protein C and protein S levels were determined from one 
blood draw. In a clinical setting, low protein levels are conﬁrmed by a second 
measurement before a patient is diagnosed as deﬁcient. A previous study 
among patients with venous thrombosis and control subjects 42 reported 
that 5 of 20 (25%) patients who initially had antithrombin levels below the 
lower limit of normal were low at a second measurement. Conﬁrmation of 
low protein C levels occurred in 15 of 22 (68%) patients and conﬁrmation 
of low protein S levels in 5 of 8 (63%) patients. Conﬁrmation occurred 
less frequently in control subjects. We acknowledge that the number of 
individuals with truly low levels of antithrombin, protein C and protein S 
will be lower than presented here.
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We studied whether family history is of additional value in predicting an 
individual’s risk of venous thrombosis once a genetic risk factor has been 
identiﬁed. We could also reverse the question and ask whether genetic 
testing provides additional prognostic value once the family history has been 
determined. This could guide decisions on starting oral contraceptive use 
or taking preventive measures during immobilization. Table 4 shows that 
environmental risk factors together with a positive family history strongly 
increase the risk of venous thrombosis. In the absence of a known genetic 
risk factor the risk is already increased more than 15-fold. Genetic testing to 
identify additional risk would then not seem useful. Moreover, the positive 
family history could well reﬂect unknown genetic risk factors. When the family 
history is negative, an environmental risk factor would increase the risk about 
10-fold to 20-fold, depending on the identiﬁcation of a genetic risk factor. 
Given the low chance of ﬁnding a genetic risk factor when the family history 
is negative, genetic testing does not seem to be cost effective in this situation.
It is important to note that the results from the current study apply to the 
risk of a ﬁrst venous thrombosis, and may not be applicable to risk of 
recurrent venous thrombosis. In fact, previous studies have shown that 
neither genetic risk factors nor family history are predictive for recurrent 
venous thrombosis 43,44.
We conclude that family history is a risk indicator for a ﬁrst venous thrombosis, 
even when a genetic risk factor has been identiﬁed. In clinical practice the 
family history may be more useful for risk assessment than thrombophilia 
tests. A positive family history represents increased susceptibility on top of 
the risk due to known genetic and environmental factors. This additional risk 
is due to unknown or unmeasured risk factors.
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ABSTRACT
Various pathways lead to the development of venous thrombosis. Risk 
factors are common and can be genetic or acquired. Since the identiﬁcation 
of factor V Leiden and prothrombin G20210A, the ﬁeld of genetic 
epidemiology has developed rapidly and many new genetic variants have 
been described in the past decade. However, the association with venous 
thrombosis is often unclear and conﬂicting results have been reported 
in various studies. The aim of this review is to describe these candidate 
predictors of venous thrombosis and to put these in perspective.
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Venous thrombosis is a complex condition in which genes and environment 
both contribute to the risk of disease. Many risk factors for venous 
thrombosis are common, and often, if not always, the coincidence of two 
or more risk factors is required to develop thrombosis. Heritable defects 
in factors that control the hemostatic balance have been identiﬁed since 
1965 (for a comprehensive review, see Mannucci 45). In that year, Egeberg 
described a family in which the incidence of venous thrombosis was higher 
and at a younger age than expected. It appeared that the affected family 
members had about 50% lower antithrombin levels than the non-affected 
family members. Deﬁciencies of protein C and protein S were identiﬁed 
in a similar manner during the 1980s. Families with a history of recurring 
venous thrombosis but no known hereditary abnormalities were studied 
to determine the role of plasma protein deﬁciencies. It appeared that 
affected family members had severely reduced protein levels of protein C 
or S. Today, numerous loss-of function mutations have been described in 
the genes encoding antithrombin, protein C, and protein S that lead to 
reduced plasma levels. In the heterozygous state these mutations lead to 
about halfnormal plasma levels. Homozygous mutations, especially in the 
antithrombin gene, are assumed to be incompatible with life.
In addition to these relatively rare protein deﬁciencies, two much more 
common genetic defects were described during the 1990s. Activated protein 
C (APC) resistance was identiﬁed as a risk factor for venous thrombosis 
in 1993. In 1994, Bertina et al found that factor V was involved in APC 
resistance. Subsequently, the factor V Leiden mutation was found by searching 
the factor V gene of APC resistant patients for mutations in APC binding- 
and cleavage sites. The second common genetic factor, prothrombin 20210 
G>A, was identiﬁed in 1996 through screening the prothrombin gene for 
abnormalities among patients with a personal and family history of venous 
thrombosis. At present, the three plasma protein deﬁciencies and the two 
mutations are the main genetic risk factors for venous thrombosis. However, 
they still explain only part of venous thrombotic events 45. The failure to 
identify a risk factor in many patients and the belief that genetic factors play 
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total ﬁbrinogen ratios. Interestingly, the FGA Thr312Ala polymorphism is 
strongly linked to this haplotype. Whether FGA Thr312Ala is a functional 
variant itself or only reﬂects the effect of the 10034C>T variation in FGG-H2 
remains to be elucidated.
Prothrombin
Prothrombin is the inactive precursor of thrombin. A principal role of 
thrombin is to cleave ﬁbrinogen to form ﬁbrin. In addition, thrombin gives 
positive feedback to the coagulation cascade by activating other coagulation 
factors and negative feedback by activating protein C in a complex with 
thrombomodulin. It inﬂuences ﬁbrinolysis also, through thrombin activatable 
ﬁbrinolysis inhibitor (TAFI). The 20210 G>A mutation in the prothrombin 
gene increases the risk of venous thrombosis by increasing plasma prothrombin 
levels (ﬁrst described by Poort et al 51. Around the 20210 position several 
additional variants were described, but there is no clear evidence that these 
rare variants contribute to the risk of venous thrombosis 52. Another common 
variant in the prothrombin gene, 19911 A>G, is also associated with slightly 
higher prothrombin levels 3,53,54. Initially, two studies reported that 19911 
A>G modulates the risk in 20210A carriers 53,55. Recently, two larger studies 
reported an increased risk associated with 19911 A>G, independently of 
other genetic risk factors 3,54.
an important role in the development of venous thrombosis stimulate the 
search for novel predictive genetic variants.
Since the identiﬁcation of prothrombin 20210 G>A in 1996, the ﬁeld of 
genetic epidemiology has evolved rapidly and many genetic variants have 
been described that might inﬂuence the risk of venous thrombosis. In this 
review we will give an overview of the main genetic factors described in 
the past decade and put the ﬁndings in perspective. The main features are 
presented in Table 1.
NOVEL GENETIC VARIANTS
Fibrinogen
Fibrinogen is the precursor of ﬁbrin, the fundamental constituent of the 
thrombus. The ﬁbrinogen molecule consists of three chains: alpha (FGA), beta 
(FGB), and gamma (FGG), each encoded by a separate gene. High levels of 
ﬁbrinogen increase the risk of venous thrombosis, mainly in elderly people 7. 
The most frequently studied polymorphism is a G>A substitution at nucleotide 
-455 in the FGB gene. This genetic variant is associated with slightly increased 
ﬁbrinogen levels but appears not to increase the risk of venous thrombosis 46,47. 
Another, less frequently studied, polymorphism in the FGA gene, 4266 A>G 
(Thr312Ala), is associated with the risk of pulmonary embolism (PE) and is 
postulated to inﬂuence ﬁbrin cross-linking 48. The 312Ala genotype leads to 
reduced clot strength and a higher risk of embolization. Ko et al found an 
FGA haplotype, covering the Thr312Ala variant, to be related to both PE 
and deep vein thrombosis (DVT) in a Taiwanese population 49. In another 
study that analyzed the association of haplotypes of the alpha, beta, and 
gamma genes and the risk of DVT, the only haplotype associated with DVT 
was a haplotype of the FGG gene, tagged by 10034 C>T (FGG-H2) 50 This 
polymorphism is located in a consensus sequence that is involved in cleavage 
and splicing of the FGG pre-mRNA. The FGG-H2 haplotype is associated 
with decreased levels of ﬁbrinogen gamma’ (FGG’) and decreased FGG’/
Factor V
Activated factor V (FVa) is a cofactor for factor Xa in the conversion of 
prothrombin to thrombin. In addition, FV is a cofactor of APC-mediated 
FVIII degradation. Factor V Leiden (1691 G>A, Arg506Gln) is a mutation 
in the major cleavage site of FVa by APC, which makes FVa more resistant 
to inactivation. Recently, all known FV missense mutations that are relatively 
common were reviewed by Vos 68. The most important variant, apart from 
factor V Leiden, is a common haplotype including several polymorphisms 
throughout the FV gene, ﬁrst described by Lunghi et al 69. This haplotype, 
FV HR2, is associated with decreased cofactor activity in FVIII inactivation 
and a more procoagulant isoform of FV. The variant responsible for the FV 
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Table 1 Candidate Predictors of Venous Thrombosis
Gene Nucleotide Amino Acid Allele 
Frequency*
Phenotype Odds Ratio†
Procoagulant proteins
FGA 4266 A>G Thr312 Ala 0,26 (G) reduced clot strength 1,8 49
FGG
10034 C>T 
(FGG-H2)
0,26 (T)
alternatively spliced 
protein
2,4 50
Prothrombin 19911 A>G 0,49 (G) 3 higher protein level 1,4 3
FV 6755 A>G (HR2) Asp2194Gly 0,07 (G)
decreased FV cofactor 
activity
1,2 56 (carriers)
FVIII 94901 C>G Asp1241Glu 0,15 (G) lower protein level 0,6 57 (carriers)
FVIII HT1 0,14 (HT1) 58 lower protein level 0,4 58 (men)
FXII 46 C>T 0,15 (T) lower protein level not replicated
FXIII G>T Val34Leu 0,24 (T) 59 higher protein activity 0,6 59
FXIII 8259 A>G His95Arg 0,08 (T) 60 higher protein activity 1,5 60
TF 1208 I/D 0,52 (D) 61 lower protein level 0,7 61
FSAP
1601 G>A 
(Gly511Gly)
-
impaired ﬁbrinolysis 
inhibition
not replicated
ACE I/D 0,51 (D) 62 higher protein level not clear
Anticoagulant proteins
TFPI 536 C>T Pro151Leu <0,01 (D) 63 not replicated
TFPI  -33 T>C 0,36 (C) higher protein level 0,6 64
EPCR 4600 A>G Ser219Gly 0,08 (G) higher sEPCR level not clear
EPCR 4678 G>C 0,34 (C) higher APC level not clear
Antiﬁbrinolytic proteins
PAI-1 4G/5G (D/I) 0,48 (5G) 65 lower protein level not clear
TAFI 505 G>A Ala147Thr 0,30 (T) higher protein level 0,7
Other
Blood group O 0,43 (O) 66 lower FVIII level 0,6 66
ZPI 728 C>T Arg67Stop <0,01(T) lower protein level 3,3 67 (carriers)
MTHFR 677 C>T Ala222Val 0,24 (T) lower protein activity not clear
* Allele frequencies as calculated in the study population referred to. When no reference is given, 
 the allele frequency for Caucasian populations (applies to almost all studies) was obtained 
 from dbSNP.
† By default, the odds ratio for homozygous carriers. For FV HR2, FVIII Asp1241Glu, FXIII His95Arg, 
 and ZPI Arg69Stop, the odds ratio for all carriers (heterozygous and homozygous) is given.
HR2 phenotype is probably 6755 A>G (Asp2194Gly) 68. Whether the FV 
HR2 haplotype affects the risk of venous thrombosis is not clear. Individual 
studies reported conﬂicting results and in a meta-analysis a pooled odds ratio 
of 1.15 (95% conﬁdence interval [CI], 0.98 to 1.36) was calculated 56.
Factor VIII
The factor VIII (FVIII) gene has been studied extensively because there is 
a clear association between FVIII levels and the risk of venous thrombosis. 
Several studies screened cleavage sites, promoter and polyadenylation regions 
of the FVIII gene but found no mutation that corresponded with either 
FVIII levels or thrombosis 70-72. However, two other studies reported lower 
FVIII levels associated with a 94901 C>G (Asp1241Glu) polymorphism that 
was therefore possibly protective for venous thrombosis 57,73. In a recent study 
of the haplotypes carrying the 1241Glu variant (HT1, HT3, HT5), the 
protective effect of 1241Glu and lower levels of FVIII were conﬁrmed, but 
seemed limited to male carriers of HT1 58. This indicates that Asp1241Glu is 
not likely to be functional but is probably linked to a functional variant. In 
addition, the risk reduction was only partially dependent on the lower levels 
of FVIII, which suggests that not only FVIII levels inﬂuence risk but also 
protein function may contribute.
Factor XII
Factor XII (FXII) is involved in both the intrinsic coagulation pathway and 
the ﬁbrinolytic pathway. Although it has been suggested that deﬁciency 
of FXII may lead to an increased risk of thrombosis, there is not enough 
evidence to conﬁrm an association. In 1998, Kanaji et al 74 described the 
FXII 46 C>T polymorphism that was associated with decreased plasma FXII 
levels. After ﬁnding FXII 46 C>T associated with FXII levels and venous 
thrombosis in a linkage study, Tirado et al reported an odds ratio of 4.8 (95% 
CI, 1.5 to 15.6) for the TT genotype 75. However, other studies could not 
conﬁrm this ﬁnding 76-78.
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Marburg I polymorphism (1601 G>A, Gly511Gly) impairs the proﬁbrinolytic 
activity of FSAP but has no effect on its FVII-activating function 84. Initially, an 
increased risk of venous thrombosis was reported for carriers of the Marburg I 
polymorphism, mainly for idiopathic cases 85. However, this ﬁnding could not 
be conﬁrmed by others 86,87.
Blood Group
ABO blood group is associated with both FVIII and von Willebrand factor 
(VWF) levels, and a reduced risk of venous thrombosis for phenotypic blood 
group O was already recognized by Jick et al 88 in 1969. The protective effect 
of blood group O is mainly explained by FVIII levels 66,89. In 2005, several 
investigators reported on the association between blood group genotype and 
venous thrombosis 66,90-92. All studies conﬁrmed the lower risk for blood group 
O (genotypes O1O1 and O1O2), and the highest risk for carriers of the A1 allele. 
Blood group O genotypes were associated with lower FVIII and VWF levels 
91,92. The protective effect is restricted to homozygous carriers of O alleles; hence 
individuals with phenotypic blood group O 90. There is some evidence that the 
risk for non-OO genotypes is higher in carriers of factor V Leiden 66.
Angiotensin-Converting Enzyme
Angiotensin-converting enzyme (ACE) stimulates platelet activation and 
regulates ﬁbrinolysis. The relationship between ACE levels and the risk of 
venous thrombosis is, however, not clear. Variation in ACE levels is largely 
explained by a 287-bp insertion/deletion (I/D) polymorphism in the ACE gene. 
Individuals with the DD genotype have higher plasma ACE than individuals 
with the II genotype 93. Initially, the DD genotype was reported to increase the 
risk of venous thrombosis 94,95. Subsequent studies reported varying associations 
between the I/D variant and venous thrombosis, as summarized by Okumus 
et al 96 and Ekim et al 97. An important conclusion from both reviews was that 
studies were heterogeneous in patient selection, with regard to etiology and 
ethnicity. The most recent and largest study found a slightly protective effect 
of the DD genotype, which was restricted to women. However, the authors 
concluded that the I/D polymorphism itself is unlikely to be functional 62.
Factor XIII
Factor XIII (FXIII) stabilizes the ﬁbrin clot by cross-linking ﬁbrin monomers. 
A genetic variant that interferes with clot stabilization is the FXIII Val34Leu 
polymorphism. The FXIII 34Leu variant is more rapidly activated and thus 
more rapidly cross-links ﬁbrin ﬁbers. However, these ﬁbers are thinner and the 
ﬁbrin clots are more solid 79. The 34Leu variant was found to be protective when 
ﬁrst studied in relation to venous thrombosis 80. Subsequent studies mostly 
failed to conﬁrm this ﬁnding, perhaps due to small study sizes, but in a meta-
analysis a pooled odds ratio of 0.63 (95% CI, 0.46 to 0.86) was computed 81. 
Recently, this protective effect was shown to depend on ﬁbrinogen levels 82. 
High levels of ﬁbrinogen also lead to less porous ﬁbrin clots, and seem to act 
synergistically with FXIII 34Leu, being protective against venous thrombosis. 
Another polymorphism was reported in the FXIII B-subunit. This is a carrier 
protein for FXIII and dissociates upon activation of FXIII. The 8259 A>G 
(His95Arg) variant leads to increased dissociation and moderately increases the 
risk of venous thrombosis 60.
Tissue Factor
Tissue factor (TF) initiates coagulation by activating factor VII. TF is expressed 
by most cells and organs and a soluble form of TF might also circulate in 
plasma. The relationship between circulating TF levels and venous thrombosis 
is not clear. Arnaud et al 61 screened the promoter region of the TF gene in 
blood donors and identiﬁed a deletion/insertion polymorphism, 1208 D/I, of 
which the 1208 D variant was associated with lower circulating TF levels and a 
lower risk of venous thrombosis in a subsequent case-control study. The coding 
region of the TF gene was screened in a case-control setting by Zawadzki et 
al 83. They found a C>T (Arg200Trp) variant that might lower monocyte TF 
concentrations, but the variant was too rare to study its effect on the risk of 
thrombosis.
Factor VII–Activating Protease
Factor VII-activating protease (FSAP) stimulates coagulation by activating 
FVII. It also stimulates ﬁbrinolysis by activating urokinase precursor. The 
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three haplotypes of which the haplotype corresponding to the 4600G genotype 
(H3) was associated with increased sEPCR levels and an increased risk of 
venous thrombosis. Uitte de Willige et al 106 identiﬁed an additional haplotype 
(H4) that also contained 4600G and was part of H3 in the study of Saposnik et 
al. In this study, carriers of H4 (not H3) had a slightly increased risk of venous 
thrombosis, which suggests that 4600G itself is not a functional variant.
Plasminogen Activator Inhibitor-1
Plasminogen activator inhibitor-1 (PAI-1) indirectly inhibits the ﬁbrinolytic 
activity of plasminogen. There is no clear relationship between PAI-levels and 
venous thrombosis 117. Dawson et al 118 described a guanine deletion/insertion 
(4G/5G) upstream of the PAI-1 gene that inﬂuences PAI-1 activity. A literature 
review regarding 4G/5G and venous thrombosis by Francis 117 showed that 
although most studies ﬁnd higher plasma levels of PAI-1 in individuals with 
4G/4G, the effect on the risk of venous thrombosis is not clear. There is some 
evidence that 4G/4G increases the risk of venous thrombosis in subgroups with 
additional genetic risk factors 65,119, but these ﬁndings need to be conﬁrmed. 
The fact that the 4G/5G variant is associated with PAI-I levels but not with 
venous thrombosis suggests that PAI-I levels have no major effect on the risk 
of venous thrombosis.
Thrombin-Activatable Fibrinolysis Inhibitor
During ﬁbrinolysis, partially degraded ﬁbrin is a cofactor for plasminogen 
activation. Thrombin-activatable ﬁbrinolysis inhibitor (TAFI) inhibits 
ﬁbrinolysis by suppressing this cofactor activity. Increased TAFI levels were 
found to be associated with a slightly increased risk of venous thrombosis. 
Zhao et al 120 described the 505 G>A polymorphism (Ala147Thr) that was 
associated with higher TAFI concentrations. In addition, several promoter 
polymorphisms (-438 A>G, 1102 T>G, 1690 G>A) and an additional 
polymorphism in the coding region (1040 C>T, Thr325Ile) were described 
that inﬂuenced TAFI levels and possibly the risk of venous thrombosis, but 
these variants were strongly linked to the 505 polymorphism 121,122. Martini 
et al 122 analyzed haplotypes constructed of -438 G>A, 505 G>A and 1040 
Tissue Factor Pathway Inhibitor
The ﬁrst step in the extrinsic coagulation pathway is inhibited by tissue factor 
pathway inhibitor (TFPI). Low TFPI levels are associated with an increased 
risk of venous thrombosis 98. Five polymorphisms have been described in 
the TPFI gene. The -399 C>T polymorphism, reported by Miyata et al 99 
was not associated with TFPI concentrations or with venous thrombosis. 
Kleesiek et al 63 screened the coding region of the gene and found a 536 C>T 
(Pro151Leu) variant that was associated with an increased risk of venous 
thrombosis but not with TFPI plasma activity and concentration. The 
association with venous thrombosis was not conﬁrmed by others 100-102. Three 
other polymorphisms were reported by Moatti et al 103,104. The 874 G>A 
(Val264Met) variant might inﬂuence TFPI levels, but it was not associated 
with venous thrombosis 98,105. The intron variant -33 T>C and the promoter 
polymorphism -287 T>C were both associated with higher TFPI levels 64,104. 
Accordingly, -33C was found to be protective for venous thrombosis 64. The 
-287 T>C variant has not yet been studied in venous thrombosis patients.
Endothelial Protein C Receptor
The endothelial protein C receptor (EPCR) is expressed on the endothelium 
of large vessels. Binding of protein C stimulates protein C activation by the 
thrombin–thrombomodulin complex. A soluble form of EPCR (sEPCR) also 
binds protein C but inhibits protein C activity. Low levels of sEPCR have 
been found to reduce the risk of venous thrombosis 106. Biguzzi et al screened 
the EPCR gene in venous thrombosis patients and found a 23-bp insertion 
(4031ins23) that impaired EPCR function, and four promoter polymorphisms 
that did not affect transcription in vitro 107,108. These variants were rare in 
both patients and control subjects and therefore the effect on thrombosis 
risk could not be established 109-111. España et al 112 reported more common 
polymorphisms in exon 4 (4600 A>G, Ser219Gly) and in the 3′UTR (4678 
G>C). The 4600G genotype was associated with increased sEPCR levels and 
the 4678C genotype was associated with increased APC levels. Conﬂicting 
results were published about the association with venous thrombosis 106,113-115. 
Two studies constructed haplotypes of the EPCR gene. Saposnik et al 116 found 
50
Chapter 3
51
C
ha
pt
er
 3
Predictive genetic variants
venous thrombosis, no predictive genetic variants are known in the genes 
encoding factor IX and factor XI. The promoter region of the FXI gene 
has been screened and two single-nucleotide polymorphisms (SNPs) were 
identiﬁed 129, but the association with plasma concentrations of FXI and 
venous thrombosis has not yet been studied. Plasma levels of factor X and 
von Willebrand factor are also related to the risk of venous thrombosis, 
but the association is dependent on levels of other coagulation factors 
66,89,130. For both factors, gene variants were studied in relation to plasma 
concentrations and the risk of venous thrombosis, but no association was 
found 72,130. Plasma concentrations of factor VII and thrombomodulin 
are not related to the risk of venous thrombosis. Some genetic variants 
were identiﬁed that were related to levels but not to the risk of venous 
thrombosis 46,47,131-134.
FUTURE PERSPECTIVES
Research Goals
All variants that were initially found to be associated with venous thrombosis 
are listed in Table 1. For each factor, the magnitude of the association with 
venous thrombosis is given in the right column. However, most of these 
ﬁndings have not yet been replicated, and others have failed to replicate. 
Failure of replication may occur for several reasons.First, many genetic 
variants of modest effect are expected to contribute to the risk of venous 
thrombosis. To detect these modest effects large sample sizes are needed. 
All of the genetic variants discussed above are at most weak risk factors and 
were studied in samples of at most several hundreds of study subjects.
Another obstacle for replication is phenotype deﬁnition. Venous thrombosis 
is a multicausal disease and genetic variants that inﬂuence the risk of disease 
are expected to affect only one of the causal pathways. The intermediate 
phenotype of that causal pathway (for example, protein levels) will be more 
strongly correlated to the genetic variant. On the other hand, when the 
C>T and found that only 505A was associated with a reduced risk of 
venous thrombosis. This was an unexpected ﬁnding because 505A is the 
variant associated with higher TAFI levels. Further research is needed to 
unravel the relationship between TAFI and venous thrombosis.
5,10-Methylenetetrahydrofolate Reductase
Increased homocysteine has been associated with venous thrombosis in 
many studies but the mechanism by which homocysteine affects coagulation 
is not clear. The common 677 C>T (Ala222Val) polymorphism in the 
5,10-methylenetetrahydrofolate reductase (MTHFR) gene, leading to a 
thermolabile variant of the enzyme, slightly increases plasma homocysteine 
levels and has been studied extensively. Odds ratios computed from a large 
meta-analysis indicate that MTHFR 677 C>T is a weak risk factor for 
venous thrombosis 123. However, we have recently studied MTHFR 677 
C>T in a large case-control study but found no evidence of an association 
with venous thrombosis 124.
Protein Z–Dependent Protease Inhibitor
Although in vitro studies suggest that protein Z–dependent protease 
inhibitor (ZPI) might inﬂuence coagulation by inhibiting FXa and FXIa 125, 
ZPI plasma levels do not seem to affect the risk of venous thrombosis 126. Van 
de Water et al 125 screened the coding region of the ZPI gene for mutations 
and identiﬁed two premature stop codons at Arg67 and Trp303 that were 
associated with venous thrombosis. However, in subsequent studies, the 
Trp303 stop codon was not detected 127 or the presence of either Arg67Stop 
or Trp303Stop was not associated with venous thrombosis 67. Recently, 
however, Corral et al 128 studied haplotypes of the ZPI gene and found the 
haplotype covering Arg67Stop to be associated with venous thrombosis 
with a 3.3-fold increased risk. Since Arg67Stop is a rare mutation, large 
studies are needed to conﬁrm this ﬁnding.
Factors VII, IX, X, XI, von Willebrand Factor, and Thrombomodulin
Despite a clear association between plasma levels and the occurrence of 
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intermediate phenotype is not associated with venous thrombosis, which is 
the case with FVII, FX, FXII, von Willebrand factor, and thrombomodulin, 
ﬁnding an association between venous thrombosis and the genetic variant is 
less likely.
Alternatively, the initial ﬁnding may have been a false-positive result. As the 
amount of genetic variants tested increases, the possibility of ﬁnding false-
positive results also increases when multiple testing is not correctly accounted 
for. The problem of false-positive ﬁndings probably accounts for many of the 
non-replicated associations.
Once a ﬁnding is replicated, the knowledge from previous studies can be used 
to further explore the relationship between the replicated variant and disease. 
This can be done by constructing haplotypes in the genes where association 
was found, as was the case in relation to the ﬁbrinogen 50, FVIII 58, and EPCR 
116 genes. In these studies, haplotypes were identiﬁed that increased the risk 
of thrombosis and probably explained the association observed before with 
a single nucleotide polymorphism. Knowledge from previous research can 
further be used to study interaction of genetic variants that seem to affect the 
same causal pathway. The synergistic effect of the FXIII Val34Leu variant and 
ﬁbrinogen levels observed by Vossen et al 82 is an example of this approach.
Clinical Implications
The ultimate goal of genetic epidemiologic research is to be able to predict each 
individual’s risk of disease on the basis of genetic and acquired factors. With a 
genetic proﬁle it would then be possible to give lifestyle recommendations or 
prophylaxis in high-risk situations to maximally reduce the risk of disease.
However, venous thrombosis is a complex disease and prediction requires an 
extensive model including many acquired and genetic factors. To be clinically 
useful, the genetic variants described above should be evaluated together with 
many other, as yet unknown, risk factors. In addition, the outcome of testing 
the genetic variant should inﬂuence treatment or preventive measures. The 
various possible or weak genetic risk factors for venous thrombosis that have 
been identiﬁed in the past years are not of clinical importance.
CONCLUSION
In the past decade, many factors have been described that might inﬂuence 
the risk of venous thrombosis. Some of these, like ABO blood group, FXIII 
Val34Leu, or haplotypes of ﬁbrinogen, FV, and FVIII, are possible novel 
predictive variants. Others have failed to replicate in subsequent studies. 
More well-designed, large studies are needed to unravel the various pathways 
that lead to the development of venous thrombosis.
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ABSTRACT  
Background Increased homocysteine levels are related to the occurrence 
of venous thrombosis, but whether this relation is causal is unclear. The 
T-variant of the common methylenetetrahydrofolate reductase (MTHFR) 
677CT polymorphism mildly increases homocysteine levels. Meta-analyses 
have demonstrated a weak effect of the MTHFR 677TT genotype on risk 
but are sensitive to selective publication of positive results. The aim of the 
present study was to evaluate the effect of the MTHFR genotype on the risk 
of venous thrombosis, overall and in subgroups of known risk factors, in a 
single large study. 
Methods In the Multiple Environmental and Genetic Assessment of risk 
factors for venous thrombosis (MEGA Study), a population-based case-
control study, we collected DNA from 4375 patients with a ﬁrst deep vein 
thrombosis of the leg or pulmonary embolism and from 4856 control 
subjects. Information about risk factors for venous thrombosis was obtained 
from questionnaires. 
Results MTHFR 677CT was not associated with the risk of venous 
thrombosis (odds ratio [95% conﬁdence interval], 0.99 [0.91-1.08] for 
the CT genotype and 0.94 [0.81-1.08] for the TT genotype). Stratiﬁcation 
by known risk factors for venous thrombosis provided no evidence of an 
association in speciﬁc groups. 
Conclusions In a single large study, MTHFR 677CT was not associated with 
the risk of venous thrombosis, and the narrow conﬁdence interval excludes 
even a small effect. Therefore, mildly elevated homocysteine levels as a result 
of MTHFR 677TT do not seem to cause venous thrombosis. There is no 
rationale for measuring the MTHFR 677CT variant for clinical purposes.
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INTRODUCTION  
Venous thrombosis is a common disease with an annual incidence of 1 to 
3 in 1000 individuals and is caused by the joint effect of environmental 
and genetic risk factors 135. One of the genetic factors that have been 
extensively studied over the past decade is a polymorphism in the gene 
encoding 5,10-methylenetetrahydrofolate reductase (MTHFR). MTHFR 
is an enzyme involved in homocysteine metabolism by converting folate, 
a cofactor for homocysteine conversion, into its major circulating form 
5-methyltetrahydrofolate. A common C>T substitution at nucleotide 677 
converts an alanine to a valine residue 136 and causes thermolability of 
the enzyme at 37°C. Homozygotes have more than 50% reduced enzyme 
activities, but the effect of reduced MTHFR activity on homocysteine levels 
is dependent on folate intake. Homocysteine levels are about 25% higher in 
homozygous carriers only when plasma folate concentration is low 137.
Hyperhomocysteinemia is associated with venous thrombosis 138 and 
therefore MTHFR 677C>T has been one of the candidate genetic risk factors 
for venous thrombosis. However, most case-control and cohort studies that 
assessed the association between MTHFR 677C>T and venous thrombosis 
reported either a weak association or no relationship at all. Because these 
studies were small and often underpowered to detect weak effects, several 
meta-analyses have been performed 123,139,140. The most recent and largest 
meta-analysis, including 8364 cases and 12 468 controls, found a small 
increase in risk for MTHFR 677TT carriers (odds ratio [OR], 1.20; 95% 
conﬁdence interval [CI], 1.08-1.32) 123. This risk increase is in line with 
the expected risk based on the association of the variant with homocysteine 
levels and the effects of hyperhomocysteinemia. The major disadvantage of 
meta-analyses, however, compared with a single large study, is the possibility 
of publication bias. Meta-analyses are based on published studies and rely 
on the quality of the collected studies. Publication bias is present when 
studies with “positive” results have a higher probability of being published 
than studies with “negative” results. It has been shown repeatedly that 
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blood sample. For practical reasons individuals with severe psychiatric 
problems or individuals who did not speak Dutch were excluded.
All participants were asked to ﬁll in a questionnaire on acquired risk factors 
for venous thrombosis, family history of venous thrombosis, and vitamin 
B supplementation. The date of diagnosis as reported by the patient in the 
questionnaire or, when missing, the date of the ﬁrst visit at the anticoagulation 
clinic served as the index date for patients and their partners. The index 
date for RDD control subjects was the date on which the questionnaire was 
completed or, when missing, the date on which the completed questionnaire 
was returned.
A blood sample was taken approximately 3 months after discontinuation 
of anticoagulant therapy. If patients continued their anticoagulant therapy, 
blood was drawn 1 year after the index date. Partner controls were invited 
for a blood draw along with their partner; RDD controls were invited after 
returning their questionnaire. Blood samples were taken from patients who 
were diagnosed before June 1, 2002, and their partners. Patients who were 
diagnosed from June 1, 2002, onwards and their partners received a cotton swab 
along with their questionnaire for collecting buccal cells. In the RDD group, 
blood samples were collected throughout the entire study period. Participants 
who refused to or were unable to provide a blood sample were offered the 
option of providing a buccal swab sample. Ideally, participants ﬁlled in a full 
questionnaire and provided a DNA sample, but a minor proportion provided 
only DNA. When the full questionnaire was not returned, we attempted to 
collect information about acquired risk factors (but not family history and 
vitamin supplementation) through a miniquestionnaire by telephone.
Of 6333 eligible patients with deep vein thrombosis of the leg or a pulmonary 
embolism, 358 died before inclusion and 271 could not be contacted. Of 
the remaining 5704 patients, 5053 (89%) participated. A DNA sample was 
donated by 4379 patients, among whom 4257 full questionnaires and 99 
miniquestionnaires were collected.
publication bias is common in the medical literature 141. Publication bias 
leads to an overestimate of the risk. Although no evidence of publication 
bias was found in the meta-analysis mentioned previously 123, it cannot 
be ruled out that studies that found no association, irrespective of sample 
size, were underrepresented. The alternative is a single large study, in which 
publication bias obviously can play no role.
Several studies have suggested that the effect of MTHFR 677C>T on venous 
thrombosis is only visible in speciﬁc subgroups with other predisposing 
genetic or environmental factors or, on the contrary, in subgroups in 
which conventional risk factors for venous thrombosis are absent 142-150. To 
adequately investigate an effect in subgroups, a large study is needed because 
only a relatively small proportion of study subjects will carry both the risk 
factor and the MTHFR 677TT genotype.
In this article, we report on the association between MTHFR 677C>T 
and venous thrombosis in a single large study. The analysis included 4375 
patients with a ﬁrst venous thrombotic event, either deep vein thrombosis 
of the leg or pulmonary embolism, and 4856 control subjects from the 
Multiple Environmental and Genetic Assessment of risk factors for venous 
thrombosis (MEGA Study).
METHODS
Study Population
Between March 1, 1999, and August 31, 2004, consecutive patients aged 18 
to 70 years with a ﬁrst venous thrombosis of the leg or arm or a pulmonary 
embolism were recruited from 6 anticoagulation clinics in the Netherlands. 
Partners of patients were invited as control subjects. An additional control 
group was recruited between January 1, 2002, and December 1, 2004, using 
a random digit dialing (RDD) method 33. The random control group was 
age- and sex frequency matched to the group of patients that provided a 
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Applied Biosystems, Foster City, Calif ) assay using a standard PCR reaction 
mix (Eurogentec, Seraing, Belgium) and allele-speciﬁc ﬂuorescent probes 
equipped with a minor groove binding moiety (Applied Biosystems).
Statistical Analysis 
Odds ratios and 95% CIs were computed as an estimate of the risk of venous 
thrombosis associated with MTHFR 677CT and TT genotypes relative to 
CC. Adjustment for age and sex was performed by logistic regression.
The association between MTHFR genotype and venous thrombosis was 
further explored through stratiﬁcation by known risk factors and computing 
ORs for the MTHFR 677TT genotype in strata of the risk factor under study, 
relative to the combined 677CT or CC genotype. Strata were made for the 
factor V Leiden, prothrombin 20210G>A, vitamin B supplementation, age 
group, family history of venous thrombosis, and the presence of predisposing 
factors for venous thrombosis.
Age was categorized as younger than 50 years (18-49 years) or 50 years and 
older (50-70 years). Family history was positive if at least 1 parent or sibling 
had venous thrombosis or a pulmonary embolism before the age of 50 
years. For 2212 (24%) of 9055 participants with a full questionnaire, family 
history status could not be determined because of incomplete data on 1 or 
more family members. Predisposing factors were surgery, immobilization, 
pregnancy or puerperium within the year preceding the index date, and 
diagnosis of malignancy before or within 6 months after the index date. 
Participants who did not have complete information on these variables (239 
[3%] of 9199 miniquestionnaires) were not included in the subgroup analysis. 
Vitamin B supplementation was deﬁned as the self-reported use of vitamin 
supplementation that contained pyridoxine hydrochloride (vitamin B
6
), folic 
acid (vitamin B
11
), or cyanocobalamin (vitamin B
12
), which are all cofactors 
for homocysteine conversion. Among 383 (4%) of 9055 participants, no 
information on vitamin B use was available. All statistical analyses were 
performed with SPSS for Windows, release 12.0.1 (SPSS Inc, Chicago, Ill).
Partners of participating patients were invited as control subjects. Of 3655 
eligible partners, 1 died before inclusion and 10 could not be contacted. Of 
the remaining 3644 partners, 2984 (82%) participated. A DNA sample was 
donated by 2602 partners. In addition, we collected DNA from 240 controls 
whose partner had venous thrombosis of the arm (n = 104), eventually 
refused to participate (n = 10), or was excluded (n = 126). Among these 2850 
partners, 2800 full questionnaires and 34 miniquestionnaires were collected.
The RDD method yielded 4350 eligible control subjects, but 4 died before 
inclusion and 88 control subjects could no longer be contacted despite 
repeated efforts. Of the remaining 4258, 3000 (70%) participated. A DNA 
sample was provided by 2023 RDD controls, among whom 2011 full 
questionnaires and 11 miniquestionnaires were collected.
To study the association between MTHFR 677C>T and venous thrombosis 
in subgroups, participants were stratiﬁed according to acquired risk factors 
as reported in the questionnaire. Participants were also stratiﬁed according 
to 2 common genetic risk factors, factor V Leiden, and prothrombin 
20210G>A. Complete genetic data on MTHFR 677C>T, factor V Leiden, 
and prothrombin 20210G>A was available from 4375 patients and 4856 
control subjects, and these were included in the present analysis.
Laboratory Analysis 
Collection and processing of blood samples and buccal swabs and 
subsequent DNA isolation has been described previously 19. Assessment of 
MTHFR 677C>T (rs1801133), factor V Leiden (rs6025), and prothrombin 
20210G>A (rs1799963) in DNA retrieved from whole blood or DNA 
from buccal swabs was initially performed by restriction fragment length 
polymorphism analysis after conventional polymerase chain reaction (PCR). 
The presence of the MTHFR 677T allele was assessed by incubation with the 
restriction enzyme HinfI. Factor V Leiden and prothrombin 20210G>A were 
analyzed in a combined method using MnlI and HindIII restriction enzymes. 
Later, all 3 polymorphisms were determined by a 5’ nuclease (Taqman; 
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the risk associated with MTHFR 677TT was somewhat higher than in 
noncarriers (OR, 1.63) but the 95% CI was wide (0.75-3.56). 
Table 2. Association of Venous Thrombosis With MTHFR 677TT Relative to 677CC/677CT in 
Subgroups of Coexisting Risk Factors
No.* Odds Ratio
(95% Conﬁdence 
Interval)
No.* Odds Ratio
(95% Conﬁdence 
Interval)
Factor V Leiden GG 8290 0.91 (0.79-1.06) Factor V Leiden 
GA/AA
941 0.94 (0.61-1.45)
Prothrombin 
20210 GG
8913 0.91 (0.79-1.05) Prothrombin 
20210 GA/AA
318 1.63 (0.75-3.56)
Age 18-49 4775 1.04 (0.87-1.26) Age 50-70 4456 0.84 (0.69-1.02)
Negative family 
history
5999 0.97 (0.82-1.15) Positive family 
history
844 0.98 (0.61-1.57)
No predisposing 
factors
5956 0.91 (0.76-1.08) Predisposing 
factors
3004 1.05 (0.81-1.35)
Vitamin B 
supplementation
2441 0.96 (0.74-1.25) No vitamin B 
supplementation
6407 0.93 (0.79-1.10)
* Total number of subjects in indicated group
The association between MTHFR 677C>T was also studied in a sub - 
group of participants who did not take vitamin supplements containing 
folic acid (vitamin B11), vitamin B6, or vitamin B12. The use of these 
vitamin supplements was more frequently reported by control subjects 
than by patients (29% vs 26%). In the subgroup without vitamin B supple-
mentation, no effect of MTHFR genotype was observed (OR, 0.93; 95% 
CI, 0.79-1.10).
The association between MTHFR 677C>T and venous thrombosis was 
further explored by stratifying patients and control subjects according to age 
at index date (age 50 or <50 years), family history of venous thrombosis, and 
RESULTS  
 
Patients included in the analysis were diagnosed as having a ﬁrst deep vein 
thrombosis of the leg (n = 2519), a ﬁrst pulmonary embolism (n = 1315), 
or both (n = 541). In total, 4375 patients and 4856 control subjects were 
included. Median age (5th-95th percentile) at the index date was 50 years 
(26-68 years) for patients and 49 years (27-67 years) for control subjects. 
Slightly more women than men were included in both groups (54% of 
patients and 53% of control subjects).
The MTHFR 677TT genotype was present in 440 patients (10%) and 517 
control subjects (11%), and the 677CT genotype in 1891 patients (43%) 
and in 2094 control subjects (43%). 
Since genotype distributions did not differ between these 2 groups, there 
was no excess risk associated with the T allele: ORs (95% CIs) of venous 
thrombosis when carrying the 677T allele were 0.99 (0.91-1.08) for 
heterozygous and 0.94 (0.81-1.08) for homozygous carriers, relative to 
677CC (Table 1). 
  
Table 1. MTHFR Genotype Distribution Among Patients With 
Venous Thrombosis and Control Subjects
MTHFR 677 C>T Cases, No (%)
(n=4375)
Control subjects, No (%)
(n=4856)
Odds Ratio
(95% Conﬁdence Interval)
CC 2044 (47) 2245 (46) 1 [Reference]
CT 1891 (43) 2094 (43) 0.99 (0.91-1.08)
TT 440 (10) 517 (11) 0.94 (0.81-1.08)
Factor V Leiden was present in 685 cases (16%) and 256 control subjects 
(5%) (Table 2). The association between MTHFR 677C>T and venous 
thrombosis did not differ between strata of factor V Leiden. Among 
patients, 224 individuals (5%) carried the prothrombin 20210A mutation 
and 94 controls (2%) were carrier. In prothrombin 20210A carriers, 
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MTHFR 677C>T has been a candidate genetic risk factor for venous thrombosis 
because its phenotype, elevated serum homocysteine level, is associated with 
venous thrombosis. In the present study, homocysteine levels were not measured, 
but elevated levels were observed in homozygous carriers of the T variant in 
many studies, including studies in the Dutch population 143. The mechanism by 
which homocysteine would affect thrombotic risk is unknown, and therefore it 
is still a matter of debate whether the relation is causal or whether homocysteine 
is a marker of other causal risk factors or the consequence of venous thrombosis. 
The study of the MTHFR genotype offers the possibility to investigate these 
various hypotheses, since a genotype cannot be a marker of another risk factor 
or a post hoc phenomenon. So, when elevated levels of homocysteine cause 
thrombosis, MTHFR 677TT is expected to be related to thrombotic risk. 
According to this reasoning, the absence of an association between MTHFR 
genotype and venous thrombosis suggests that the association between elevated 
homocysteine levels and venous thrombosis is not causal. 
Another way to disentangle causal and noncausal effects is to perform 
an experiment. If hyperhomocysteinemia causes thrombosis, lowering 
homocysteine level is expected to protect those with the MTHFR 677TT 
genotype from developing thrombosis. Several randomized trials in which 
homocysteine level was lowered by vitamin B supplementation have been 
performed or are still ongoing, both in arterial and venous disease. Three trials 
on the effect of lowering homocysteine level on arterial thrombosis have been 
completed 152-154, and 1 trial examined the effect in venous thrombosis 155. 
Despite a decrease in homocysteine levels in the vitamin treatment group, none 
of these trials showed a beneﬁcial effect on disease outcome. Thus, the results of 
these trials do not support the hypothesis that high levels of homocysteine cause 
thrombosis. It should be noted, however, that these trials examined the effect of 
lowering homocysteine level on recurrent thrombosis, not on a ﬁrst event. 
Alternatively, the effect of thermolabile MTHFR on homocysteine levels may 
be too small to cause thrombosis on its own. In the Leiden Thrombophilia 
Study 138, the risk of thrombosis was only increased when homocysteine 
the presence of predisposing factors for venous thrombosis. In none of these 
strata was an effect of MTHFR 677TT observed.
Adjustment for age or sex, stratifying patients according to diagnosis 
(thrombus in the leg, pulmonary embolism, or both), excluding study 
subjects with cancer, or restricting the control group to either partners of 
patients or RDD control subjects did not change these observations. 
COMMENT  
In the MEGA Study, a very large population-based case-control study, 
MTHFR 677C>T was not associated with the risk of venous thrombosis. 
Stratiﬁcation by factor V Leiden, prothrombin 20210G>A, family history, 
age, presence of predisposing factors, and vitamin B supplementation did not 
provide evidence of an association in speciﬁc groups.
These results should be seen in the light of many conﬂicting study results. 
As summarized in 3 meta-analyses, the majority of previous single studies 
found no association. From these meta-analyses mildly elevated ORs of 
1.29 (95% CI, 1.08-1.54) 140, 1.2 (95% CI, 1.1-1.4) 139, and 1.20 (95% 
CI, 1.08-1.32) were calculated 123. These 3 meta-analyses mostly included 
the same single studies. The most recent one was the largest and included 
20 832 study subjects from 53 studies 123. When these single studies were 
grouped by population, a slightly increased risk of venous thrombosis was 
associated with the MTHFR 677TT genotype in European populations 
(OR, 1.15; 95% CI, 1.02-1.28). In total, 30 European case-control studies 
were included, with 1280 subjects in the largest single study 151. If this meta-
analysis 123 were repeated to include the MEGA Study, the risk estimate for 
European studies would decrease to 1.06 (95% CI, 0.96-1.16). The absence 
of any association in the present analysis, which is many times larger than any 
previously published case-control study, suggests that there may have been an 
overrepresentation in the literature of studies with positive results.
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was observed. Some studies found an association in individuals in whom 
other known risk factors were absent 147, while others suggested that MTHFR 
677C>T mainly affects the risk of venous thrombosis in cooperation with 
genetic or acquired risk factors 142,143,150. Again, small study sizes might 
account for these conﬂicting results. The MEGA Study was large enough to 
make sufﬁciently large strata. No association between MTHFR genotype and 
venous thrombosis was observed within any of these strata. 
Taken together, no evidence was found for an association between MTHFR 
677C>T and the risk of venous thrombosis. There is no rationale for 
measuring the MTHFR 677C>T variant for clinical purposes.
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concentrations were above 2.43 mg/L (>18 μmol/L), compared with a 
reference level below 1.62 mg/L (<12 μmol/L), which corresponds to 
at least 50% higher homocysteine concentrations. The 25% increase in 
homocysteine concentrations that is generally observed in individuals with 
the MTHFR 677TT genotype may therefore not be enough in most cases to 
cause thrombosis.
The MTHFR 677TT genotype increases homocysteine levels only when 
combined with low vitamin B levels. Sufﬁcient intake of folic acid (vitamin 
B
11
), vitamin B
6
, or vitamin B
12
 normalizes serum homocysteine in MTHFR 
677TT carriers 156,157. Therefore, the use of vitamin supplements could mask 
a possible association between MTHFR genotype and venous thrombosis. In 
the MEGA Study, the association between MTHFR genotype and venous 
thrombosis did not depend on vitamin B supplementation as reported in the 
questionnaire. 
If MTHFR 677C>T is only a weak risk factor for venous thrombosis, 
it may only be discernible in individuals with a speciﬁc predisposition for 
developing venous thrombosis. A number of studies have evaluated the joint 
effect of MTHFR 677C>T and predisposing genetic factors, mainly factor V 
Leiden and prothrombin 20210G>A. Factor V Leiden was most frequently 
studied, but owing to the small numbers in strata of the combined factors, 
risk estimates in these studies had wide conﬁdence intervals 142,144,145,148,149. 
Only 1 study showed an association between MTHFR 677C>T in carriers 
of factor V Leiden 142. None of the studies that focused on the coexistence 
of MTHFR 677C>T and prothrombin 20210G>A found evidence of effect 
modiﬁcation 144,146. The MEGA Study conﬁrms these negative results. 
Other factors previously studied in relation to the MTHFR genotype and 
venous thrombosis were age, family history of venous thrombosis, and 
presence of acquired risk factors such as recent surgery, immobilization, 
malignancy, and pregnancy. In previous studies, different results were 
reported about speciﬁc subgroups in which an effect of MTHFR genotype 
70
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ABSTRACT 
Context The genetic causes of deep vein thrombosis (DVT) are not fully 
understood. 
Objective To identify single-nucleotide polymorphisms (SNPs) associated with 
DVT. 
Design, Setting, and Patients We used 3 case-control studies of ﬁrst DVT. A 
total of 19 682 gene-centric SNPs were genotyped in 443 cases and 453 controls 
from the Leiden Thrombophilia Study (LETS, 1988-1992). Twelve hundred six 
SNPs associated with DVT were reinvestigated in the Multiple Environmental 
and Genetic Assessment of Risk Factors for Venous Thrombosis study (MEGA-
1, 1999-2004) in a subset of 1398 cases and 1757 controls. Nine SNPs associated 
with DVT in both LETS and MEGA-1 were investigated a third time in 1314 
cases and 2877 controls from MEGA-2, a second subset of MEGA. Additional 
SNPs close to one SNP in CYP4V2 were genotyped in LETS and MEGA-1. 
Main Outcome Measure Odds ratios (ORs) for DVT were estimated by 
logistic regression. False discovery rates served to investigate the effect of multiple 
hypothesis testing. 
Results Of 9 SNPs genotyped in MEGA-2, 3 were strongly associated with DVT 
(P < .05; false discovery rate ≤.10): rs13146272 in CYP4V2 (risk allele frequency, 
0.64), rs2227589 in SERPINC1 (risk allele frequency, 0.10), and rs1613662 in 
GP6 (risk allele frequency, 0.84). The OR for DVT per risk allele was 1.24 
(95% conﬁdence interval [95%CI], 1.11-1.37) for rs13146272, 1.29 (95% CI, 
1.10-1.49) for rs2227589, and 1.15 (95% CI, 1.01-1.30) for rs1613662. In the 
region of CYP4V2, we identiﬁed 4 additional SNPs (in CYP4V2, KLKB1, and 
F11) that were also associated with both DVT (highest OR per risk allele, 1.39; 
95% CI, 1.11-1.74) and coagulation factor XI level (highest increase per risk 
allele, 8%; 95% CI, 5%-11%). 
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INTRODUCTION 
The incidence of deep vein thrombosis (DVT) is 1 per 1000 person-years 1. 
The 10-year recurrence risk is 30% 158. Deep vein thrombosis can lead to 
life-threatening pulmonary embolism 159. Deep vein thrombosis is caused 
by acquired and genetic risk factors. Acquired risk factors include age, 
hospitalization, cancer, pregnancy, hormone therapy, and surgery 158. Family 
and twin studies indicate that genetics accounts for about 60% of the risk for 
DVT 160,161. Deﬁciencies of natural anticoagulants antithrombin, protein C, 
and protein S are strong risk factors for DVT; however, the variants causing 
these deﬁciencies are rare and explain only about 1% of all DVTs 6. Two 
more common genetic variants, Factor V Leiden (FVL) and prothrombin 
G20210A, have been consistently found to be associated with DVT 51,162 but 
still only explain a fraction of the DVT events 6. It has been suggested that 2 
or more risk factors are needed for thrombosis 6,36,163.
The identiﬁcation of additional common gene variants associated with DVT 
will improve the ability to predict risk for DVT and increase understanding 
of this disease. Therefore, we investigated whether any of 19 682 primarily 
missense single-nucleotide polymorphisms (SNPs) were associated with DVT 
in 3 large case-control studies.
METHODS 
Study Populations and Data Collection 
The 3 studies (LETS, MEGA-1 and MEGA-2) in the present analysis are 
derived from 2 large population-based case-control studies: the Leiden 
Thrombophilia Study (LETS) 17 and the Multiple Environmental and 
Genetic Assessment of Risk Factors for Venous Thrombosis (MEGA study) 
19. These studies were approved by the Medical Ethics Committee of the 
Leiden University Medical Center, Leiden, the Netherlands. All participants 
gave oral informed consent for LETS and written for MEGA to participate.
Conclusions We identiﬁed SNPs in several genes that were associated 
with DVT. We also found SNPs in the region around the SNP in CYP4V2 
(rs13146272) that were associated with both DVT and factor XI levels. 
These results show that common genetic variation plays an important role in 
determining thrombotic risk. 
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selected because of their potential to affect gene function or expression 164. 
Most SNPs (69%) are missense. Another 24% of the SNPs are located in 
transcription factor binding sites or in untranslated regions of mRNA, which 
could affect messenger RNA expression or stability. Ninety-one percent of 
the SNPs studied have minor allele frequencies of at least 5% in whites. 
Information on all SNPs tested and primer sequences are available on 
request.
The design of the SNP association study is presented in the Figure. First, 
all 19 682 SNPs were tested in pooled DNA samples of LETS (http://www.
ncbi.nlm.nih.gov/projects/SNP). Single-nucleotide polymorphisms that 
were associated with DVT (P ≤ .05) were tested in pooled DNA samples 
of MEGA-1. Single-nucleotide polymorphisms that were associated in both 
LETS and MEGA-1 pools (P ≤ .05) were conﬁrmed by genotyping individual 
samples of LETS and MEGA-1. Single-nucleotide polymorphism genotypes 
consistently associated with DVT in LETS and MEGA-1 (P ≤ .05) were 
genotyped in MEGA-2.
Allele Frequency and Genotype Determination 
DNA concentrations were standardized to 10 ng/μL using PicoGreen (Molecular 
Probes, Invitrogen Corp, Carlsbad, California) ﬂuorescent dye. DNA pools, 
typically of 30 to 100 samples, were assembled based on case-control status, sex, 
age, and factor V Leiden status. DNA pools were made by mixing equal volumes 
of standardized DNA solution from each individual sample. Each allele was 
ampliﬁed separately by polymerase chain reaction (PCR) using 3 ng of pooled 
DNA. In the pooled stage, we used 6 case pools and 4 control pools for LETS, 
and 13 case pools and 18 control pools for MEGA-1. Allele frequencies in 
pooled DNA were determined by kinetic polymerase chain reaction (kPCR) 165. 
Duplicate kPCR assays were run for each allele and the ampliﬁcation curves 
from these assays were used to calculate the allele frequencies of the SNP 165. 
Genotyping of individual DNA samples was similarly performed using 0.3 
ng of DNA in kPCR assays 165 or using multiplexed oligo ligation assays 166. 
Genotyping accuracy of the multiplex method and kPCR has been assessed in 
LETS Population 
Collection and ascertainment of DVT events in LETS has been described 
previously.11 Brieﬂy, 474 consecutive patients, 70 years or younger, without a 
known malignancy were recruited between January 1, 1988, and December 
30, 1992, from 3 anticoagulation clinics in the Netherlands. For each patient, 
an age- and sex-matched control participant without a history of DVT was 
enrolled. Participants completed a questionnaire on risk factors for DVT 
and provided a blood sample. No ethnicity information was collected. After 
exclusion of 52 participants due to inadequate sample, 443 cases and 453 
controls remained in the analyses.
MEGA-1 and MEGA-2 Studies 
Collection and ascertainment of DVT events in MEGA has been described 
previously 19,20. MEGA enrolled consecutive patients aged 18 to 70 years 
who presented with their ﬁrst diagnosis of DVT or pulmonary embolism 
(PE) at any of 6 anticoagulation clinics in the Netherlands between March 
1, 1999, and May 31, 2004. Control subjects included partners of patients 
and random population control subjects frequency-matched on age and sex 
to the patient group. Participants completed a questionnaire on risk factors 
for DVT and provided a blood or buccal swab sample. The questionnaire 
included an item on parent birth country as a proxy for ethnicity.
For the present analyses, we split the MEGA study to form 2 case-control 
studies, based on recruitment date and sample availability (blood or buccal 
swab). We excluded those with isolated pulmonary embolism or a history 
of malignant disorders to obtain a study population similar to that of the 
LETS population. The ﬁrst subset, MEGA-1, included 1398 cases and 1757 
controls who all donated a blood sample. The remaining 1314 cases and 
2877 controls who donated either a blood sample or a buccal swab sample 
were included in MEGA-2.
SNP Association Study 
The 19 682 SNPs tested in this study are located in 10 887 genes and were 
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3 previous studies, and the overall concordance of the genotype calls from 
these 2 methods was greater than 99% 164,167,168. The SNPs associated with 
DVT in MEGA-2 were successfully genotyped in more than 95% of the 
participants in LETS, MEGA-1, and MEGA-2.
Gene Variants and DVT Risk in the CYP4V2 Region 
The rs13146272 SNP in the gene CYP4V2 was most strongly associated with 
DVT in the SNP association study. To investigate whether other SNPs in this 
region are associated with DVT, we used results from the HapMap Project 169 
to identify a region surrounding rs13146272 (chromosome 4:187,297,249-
187,467,731). This region contained 149 SNPs with allele frequencies of 
more than 2% (HapMap NCBI build 36). Allele frequencies and linkage 
disequilibrium were calculated from the SNP genotypes in the HapMap 
Centre d’Etude du Polymorphisme Humain (CEPH) population, which 
includes Utah residents with ancestry from northern and western Europe. 
We selected 48 of these 149 SNPs for genotyping, as surrogates for 142 of 
the 149 SNPs in this region that were either directly genotyped or in strong 
linkage disequilibrium (r 2>0.8) with at least 1 of the 48 genotyped SNPs 
(the remaining 7 of the 149 SNPs were in low-linkage disequilibrium with 
rs13146272 (r 2<0.2) and therefore not likely to be the cause of the observed 
association). The 48 SNPs were chosen using pairwise tagging in Tagger 
(implemented in Haploview 170). The 48 SNPs were initially investigated in 
LETS, and SNPs that were equally or more strongly associated with DVT 
than rs13146272 were investigated in MEGA-1.
Factor XI Assays 
Factor XI antigen measurements in LETS were described previously 171. In 
MEGA, factor XI levels were measured on a STA-R coagulation analyzer 
(Diagnostica Stago, Asnières, France). STA calcium chloride solution was 
used as an activator, STA Unicalibrator was used as a reference standard, 
and Preciclot plus I (normal factor XI range) was used as control plasma. 
The intraassay coefﬁcient of variation was 5.8% (10 assays). The interassay 
coefﬁcient of variation was 8.7% (48 assays).
Statistical Analysis 
Deviations from Hardy-Weinberg expectations were assessed using an exact 
test in controls 172. For pooled DNA analysis, a Fisher exact test was used 
to evaluate allele frequency differences between cases and controls. For the 
ﬁnal set of SNPs, logistic regression models were used to calculate the odds 
ratio (OR), 95% conﬁdence interval (95% CI), and 2-sided P value for the 
association of each SNP with DVT and to adjust for age and sex. For each 
SNP, we calculated the OR per genotype relative to noncarriers of the risk 
allele, and the risk allele OR from an additive model. This risk allele OR 
Figure. Flowchart of the Approach Used to Identify SNPs Associated With Deep Vein Thrombosis
a  Only 9 SNPs were subsequently tested in MEGA-2 because assays for the other 9 were not 
available.
No. of SNPs genotyped
STAGE 1 19682 SNPs LETS pooled DNA samples
 443 Cases
 453 Controls
MEGA-1 pooled DNA samples
 1398 Cases
 1757 Controls
LETS and MEGA-1
 Genotyping of individual samples
MEGA-2
 Genotyping of individual samples
 1314 Cases
 2877 Controls
STAGE 2 1206 SNPs
STAGE 3 104 SNPs
STAGE 4 9 SNPs a
Sample No. of SNPs associated with
deep vein thrombosis (P< .05)
1206 SNPs
104 SNPs
18 SNPs
3 SNPs
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Table 1. Characteristics of Cases and Controls in LETS, MEGA-1, and MEGA-2
        LETS             MEGA-1         MEGA-2
Cases
(n=443)
Controls
(n=453)
Cases
(n=1398)
Controls
(n=1757)
Cases
(n=1314)
Controls
(n=2877)
Men, No. (%) 190 (43) 192 (42) 652 (47) 843 (48) 633 (48) 1348 (47)
Age, Mean (SD) 45 (14) 45 (14) 47 (13) 48 (12) 48 (13) 47 (12)
Both parents born 
in North-West 
Europe, N(%)a
- - 1247 (91) 1609 (92) 1149 (90) 2527 (89)
a No information on birth country was collected in LETS.
can be interpreted as the risk increase per copy of the risk allele, and the 
corresponding P value was used to decide whether the SNP was associated 
with DVT (P ≤ .05). For SNPs on the X chromosome the analysis was 
conducted separately in men and women.
The OR (95% CI) for SNPs in the CYP4V2 region was estimated by logistic 
regression with adjustment for factor XI levels and other SNPs in the region. 
Differences in factor XI level between groups were tested with t tests, and 
changes in factor XI level per allele were estimated by linear regression.
Analyses were done using SAS version 9 (SAS Institute Inc, Cary, North 
Carolina) and SPSS for Windows, 14.0.2 (SPSS Inc, Chicago, Illinois).
False Discovery Rate 
Studies of thousands of SNPs can lead to false-positive associations. Therefore, we 
performed 2 replications after the initial discovery stage in LETS and calculated 
the false discovery rate for the SNPs genotyped in MEGA-2. The false discovery 
rate estimates the expected fraction of false positives among a group of SNPs; 
and is a function of the P values and the number of tests 173. False discovery rates 
were estimated using the 2-sided, unadjusted P value from the additive model. 
We used a false discovery rate of 0.10 as a criterion for further analysis (for a 
false discovery rate of 0.10, one would expect 10% of the SNPs in the group 
considered associated to be false positives).
RESULTS 
Baseline characteristics of the participants are presented in Table 1.
SNPs Associated With DVT in LETS and MEGA-1 
In LETS, we investigated 19 682 SNPs by comparing the allele frequencies 
of patients and controls using pooled DNA samples 165. We found that 1206 
of these 19 682 SNPs were associated (P ≤ .05) with DVT. These 1206 SNPs 
were then investigated in patients and controls from MEGA-1 using pooled 
DNA samples. The SNPs that were associated with DVT in both LETS and 
MEGA-1 were conﬁrmed by genotyping in both studies, and we found that 
18 SNPs were consistently (with the same risk allele) associated with DVT 
(P ≤ .05) in both LETS and MEGA-1 (Table 2).
SNPs Associated with DVT in MEGA-2
Nine of these 18 SNPs were subsequently tested in MEGA-2 for association 
with DVT (Table 3); assays for the other 9 SNPs were not available at the 
time. The genotypes of these 9 SNPs did not deviate from the Hardy-
Weinberg equilibrium (P ≤ .01) in the LETS and MEGA controls.
To account for the many tests, we estimated the false discovery rate for the 
SNPs tested in MEGA-2. In Table 2, factor V Leiden and the prothrombin 
G20210A mutation are presented for reference. Because these variants were 
not included in the SNP association study, we did not calculate their false 
discovery rate. For the SNP in F9 (rs6048), we only included men because in 
women, no association with DVT was observed in LETS and MEGA-1. We 
found that 3 SNPs were again associated with DVT in MEGA-2 (P ≤ .05), 
with false discovery rates ≤ .10. These 3 SNPs were in the genes CYP4V2, 
SERPINC1, and GP6. The 4 SNPs with the next lowest P values (ranging 
from .06-.15) also had low false discovery rates (≤ .20). These SNPs were 
in the genes RGS7, NR1I2, NAT8B, and F9. The risk allele frequencies for 
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Table 2. Association of 18 SNPs From the SNP Association Study and Factor V Leiden and 
Prothrombin G20210A With Deep Vein Thrombosis in the LETS and MEGA-1 Studiesa
         No. (%) of Alleles
Chr Gene SNP ID SNP Typeb Study Risk 
Allele
Cases Controls OR (95% CI)c P-
Value
3 NR1I2 rs1523127 5’UTR LETS C 373 (42) 300 (33) 1.44 (1.19-1.73) <.001
MEGA-1 1185 (42) 1373 (39) 1.15 (1.04-1.27) .008
19 GP6 rs1613662 Ser219Pro LETS A 749 (85) 725 (80) 1.36 (1.07-1.74) .01
MEGA-1 2318 (84) 2823 (81) 1.21 (1.06-1.38) .004
17 APOH rs1801690 Ser335Trp LETS C 850 (97) 852 (95) 1.65 (1.02-2.68) .04
MEGA-1 2676 (96) 3312 (94) 1.42 (1.12-1.79) .004
2 NAT8B rs2001490 Ala112Gly LETS C 382 (43) 348 (38) 1.23 (1.01-1.49) .04
MEGA-1 1118 (40) 1301 (37) 1.14 (1.03-1.26) .01
1 SERPINC1 rs2227589 Intronic LETS T 105 (12) 78 (9) 1.42 (1.04-1.94) .03
MEGA-1 303 (11) 313 (9) 1.24 (1.05-1.47) .01
7 MET rs2237712 Intronic LETS G 45 (5) 27 (3) 1.68 (1.05-2.70) .03
MEGA-1 119 (4) 110 (3) 1.38 (1.06-1.80) .02
11 EPS8L2 rs3087546 Leu101Leu LETS T 522 (60) 487 (54) 1.26 (1.04-1.52) .02
MEGA-1 1637 (59) 1964 (56) 1.12 (1.01-1.24) .03
6 CASP8AP2 rs369328 Lys93Lys LETS A 461 (52) 406 (45) 1.35 (1.11-1.63) .002
MEGA-1 1420 (51) 1680 (48) 1.13(1.02-1.24) .02
1 SELP rs6131 Asn331Ser LETS T 196 (22) 161 (18) 1.29 (1.03-1.62) .03
MEGA-1 589 (21) 636 (18) 1.21 (1.06-1.36) .003
19 ZNF544 rs6510130 Asp203His LETS G 33 (4) 13 (1) 2.54 (1.34-4.83) .004
MEGA-1 78 (3) 64 (2) 1.56 (1.11-2.18) .01
1 RGS7 rs670659 Intronic LETS C 617 (70) 584 (64) 1.27 (1.04-1.54) .02
MEGA-1 1864 (67) 2249 (64) 1.13 (1.01-1.25) .03
2 TACR1 rs881 3’UTR LETS C 745 (85) 713 (80) 1.38 (1.07-1.77) .01
MEGA-1 2356 (85) 2894 (83) 1.15 (1.01-1.32) .04
4 CYP4V2 rs13146272 Lys259Gln LETS A 611 (69) 588 (65) 1.22 (1.00-1.49) .05
MEGA-1 1896 (68) 2245 (64) 1.19 (1.07-1.32) .001
1 F5 rs4524 Arg858Lys LETS T 708 (80) 671 (74) 1.36 (1.09-1.69) .006
MEGA-1 2184 (79) 2608 (74) 1.26 (1.12-1.42) <.001
1 SMOYKEEBO/F5 rs6016 Ile736Ile LETS G 704 (80) 668 (74) 1.35 (1.09-1.69) .006
MEGA-1 2188 (79) 2615 (75) 1.27 (1.13-1.43) < .001
1 C1orf114 rs3820059 Ser172Phe LETS A 320 (36) 269 (30) 1.34 (1.10-1.64) .004
MEGA-1 1065 (38) 1169 (33) 1.22 (1.10-1.35) <.001
         No. (%) of Alleles
Chr Gene SNP ID SNP Typeb Study Risk 
Allele
Cases Controls OR (95% CI)c P-
Value
X F9 rs6048 Ala194Thr LETS 
Men
A 146 (77) 128 (67) 1.74 (1.10-2.74) .02
LETS 
Women
225 (70) 238 (68) 1.09 (0.84-1.42) .50
MEGA-1 
Men
464 (73) 566 (68) 1.26 (1.00-1.58) .05
MEGA-1 
Women
674 (72) 818 (71) 1.04 (0.90-1.21) .61
X ODZ1 rs2266911 Intronic LETS 
Men
C 161 (85) 147 (77) 1.66 (0.99-2.79) .06
LETS 
Women
422 (83) 418 (80) 1.26 (0.91-1.73) .17
MEGA-1 
Men
556 (85) 671 (80) 1.47 (1.12-1.94) .006
MEGA-1 
Women
1234 (82) 1430 (78) 1.25 (1.05-1.48) .01
1 F5 (Leiden) rs6025 Arg534Gln LETS A 95 (11) 14 (2) 7.19 (4.05-(12.77) <.001
MEGA-1 291 (10) 96 (3) 4.10 (3.23-5.21) <.001
11 F2 (G20210A) rs1799963 3’UTR LETS A 28 (3) 10 (1) 2.98 (1.43-6.20) <.001
    MEGA-1 81 (3) 37 (1) 2.89 (1.94-4.29) <.001
a All gene symbols, rs numbers, SNP types and chromosome numbers are from NCBI build 36.
b The ﬁrst amino acid corresponds to the non risk allele.
c  ORs were estimated by logistic regression using an additive model. Sex was included as a 
covariate in logistic regression models containing markers residing on the X chromosome 
and the number of risk alleles for these SNPs were coded as 0 or 1 for males and 0, 1 or 2 for 
females.
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Table 3. Associations of SNPs From the SNP Association Study With Deep Vein Thrombosis 
in MEGA-2a
No. (%) of genotypes
Chromo-
some
Gene SNP Risk 
Allele b
Genotype c Cased Controld OR (95% Cl) P value FDR e
4 CYP4V2 rs13146272 A CC 121 (10) 352 (13) 1 [Reference]
CA 478 (41) 1178 (45) 1.18 (0.94-1.49)
AA 561 (48) 1094 (42) 1.49 (1.19-1.88)
Additive (69) (64) 1.24 (1.11-1.37) <.001 <.001
1 SERPINC1 rs2227589 T CC 1001 (77) 2325 (82) 1 [Reference]
CT 278 (21) 483 (17) 1.34 (1.13-1.58)
TT 15 (1) 28 (1) 1.24 (0.66-2.34)
Additive (12) (11) 1.29 (1.10-1.49) <.001 0.004
19 GP6 rs1613662 A GG 29 (2) 89 (3) 1 [Reference]
GA 355 (27) 835 (29) 1.31 (0.84-2.02)
AA 915 (70) 1924 (68) 1.46 (0.95-2.24)
Additive (84) (82) 1.15 (1.01-1.30) 0.03 0.10
1 RGS7 rs670659 C TT 129 (10) 355 (13) 1 [Reference]
TC 615 (48) 1326 (47) 1.28 (1.02-1.60)
CC 548 (42) 1153 (41) 1.31 (1.04-1.64)
Additive (66) (64) 1.10 (1.00-1.22) 0.06 0.13
3 NR1I2 rs1523127 C AA 480 (37) 1097 (39) 1 [Reference]
AC 598 (46) 1340 (47) 1.02(0.88-1.18)
CC 220 (17) 409 (14) 1.23 (1.01-1.50)
Additive (40) (38) 1.09 (0.99-1.20) 0.07 0.13
2 NAT8B rs2001490 C GG 490 (38) 1122 (39) 1 [Reference]
GC 603 (46) 1334 (47) 1.04 (0.90-1.19)
CC 205 (16) 394 (14) 1.19 (0.98-1.45)
Additive (39) (37) 1.08 (0.98-1.19) 0.12 0.18
X F9 
(men)
rs6048 A Additive (73) (70) 1.17 (0.94-1.45) 0.15 0.20
X F9 
(women)
rs6048 A GG 56 (8) 148 (10) 1 [Reference]
GA 275 (41) 615 (41) 1.18 (0.84-1.66)
AA 343 (51) 752 (50) 1.21 (0.86-1.68)
Additive (71) (70) 1.07 (0.93-1.23) 0.37 NA 
No. (%) of genotypes
Chromo-
some
Gene SNP Risk 
Allele b
Genotype c Cased Controld OR (95% Cl) P value FDRe
19 ZNF544 rs6510130 G CC 1192 (95) 2626 (95) 1 [Reference]
CG 60 (5) 137 (5) 0.97 (0.71-1.32)
GG 0 (0) 4 (0) -
Additive (2) (3) 0.91 (0.67-1.24) 0.56 0.63
11 MET rs2237712 G AA 1183 (93) 2528 (93) 1 [Reference]
AG 86 (7) 184 (7) 1.00 (0.77-1.30)
GG 3 (0) 3 (0) 2.14 (0.43-10.6)
Additive (4) (4) 1.03 (0.80-1.33) 0.79 0.79
1 F2 rs1799963 A GG 1219 (94) 2794 (98) 1 [Reference]
GA 76 (6) 55 (2) 3.17 (2.22-4.51)
AA 0 (0) 0 (0) -
Additive (3) (1) 3.17 (2.22-4.51) <.001 NA
1 F5 rs6025 A GG 1029 (81) 2646 (95) 1 [Reference]
GA 235 (18) 140 (5) 4.32 (3.46-5.39)
AA 8 (0) 2 (0)
10.30 (2.18-
48.52)
  Additive (10) (3) 4.24 (3.42-5.26) <.001 NA 
Abbreviations: NA, not applicable, not in FDR analysis.
a All gene symbols, rs numbers, SNP types and chromosome numbers are from NCBI build 36.
b Risk increasing allele identiﬁed in LETS and MEGA-1.
c In the additive model, the increase in risk per copy of the risk allele is calculated
d For the additive model, only the allele frequency is presented, not the count.
e  P value from the additive model was used for FDR estimation. Factor V Leiden and the 
prothrombin 20210A mutation are presented for reference. Because these variants were not 
included in the SNP association study, we did not calculate their FDR. F9 FDR was calculated 
for men only
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Table 4. 48 SNPs in CYP4V2 Region Genotyped in the Leiden Thrombophilia Studya
       Risk allele (%)
 
 
 
rs number Geneb SNP Typec Case Control OR
(95% CI)d
P
rs7686244 - intergenic 39 37 1.11 (0.91 - 1.34) 0.30
rs4862650 DKFZP564J102 Gly41Lys 11 10 1.10 (0.82 - 1.49) 0.52
rs4862653 DKFZP564J102 Gly146Lys 11 10 1.09 (0.80 - 1.48) 0.58
rs2276922 DKFZP564J102 Pro241Leu 27 25 1.10 (0.89 - 1.36) 0.38
rs2276921 DKFZP564J102 intronic 49 48 1.04 (0.87 - 1.26) 0.65
rs2276920 DKFZP564J102 intronic 21 19 1.09 (0.86 - 1.38) 0.47
rs1877321 DKFZP564J102 intronic 79 76 1.19 (0.95 - 1.48) 0.13
rs2276919 DKFZP564J102 intronic 74 73 1.04 (0.85 - 1.28) 0.70
rs13141433 DKFZP564J102 intronic 87 85 1.12 (0.87 - 1.45) 0.37
rs11733307 DKFZP564J102 intronic 46 43 1.13 (0.94 - 1.35) 0.21
rs2241818 DKFZP564J102 intronic 21 19 1.16 (0.92 - 1.46) 0.22
rs6552959 DKFZP564J102 intronic 35 33 1.08 (0.89 - 1.30) 0.46
rs10017419 - intergenic 42 41 1.04 (0.86 - 1.24) 0.70
rs7676755 CYP4V2 intronic 19 18 1.08 (0.84 - 1.38) 0.55
rs13146272 CYP4V2 Gln259Lys 69 65 1.22(1.00 - 1.49) 0.05
rs7687961 CYP4V2 intronic 83 81 1.19 (0.93 - 1.51) 0.16
rs3817184 CYP4V2 splice site 47 44 1.15 (0.96 - 1.39) 0.13
rs3736456 CYP4V2 Cys282Cys 96 94 1.49 (0.96 - 2.32) 0.08
rs2276917 CYP4V2 intronic 64 63 1.07 (0.89 - 1.30) 0.46
rs3733402 KLKB1 Ser143Asn 56 55 1.04 (0.87 - 1.25) 0.67
rs4253259 KLKB1 intronic 95 94 1.27 (0.84 - 1.92) 0.25
rs4253260 KLKB1 intronic 85 84 1.14 (0.88 - 1.47) 0.31
rs4253301 KLKB1 Ala381Ser 89 88 1.15 (0.86 - 1.55) 0.35
rs2292423 KLKB1 intronic 47 43 1.16 (0.97 - 1.40) 0.11
rs3775302 KLKB1 intronic 89 86 1.24 (0.95 - 1.64) 0.12
rs4253325 KLKB1 Gln560Arg 92 89 1.37 (1.01 - 1.86) 0.04
rs925453 KLKB1 Asn587Asn 71 71 1.00 (0.81 - 1.23) 0.99
rs3087505 KLKB1 3’UTR 92 90 1.26 (0.91 - 1.76) 0.17
rs3822055 KLKB1 3’near gene 20 18 1.14 (0.89 - 1.46) 0.30
rs6844764 - intergenic 60 56 1.16 (0.96 - 1.40) 0.13
rs13135645 - intergenic 86 83 1.22 (0.94 - 1.58) 0.14
rs3756008 F11 5’near gene 47 42 1.22 (1.02 - 1.46) 0.03
these 7 SNPs ranged from 11% to 82% among the controls. The OR for 
homozygous carriers, compared with homozygotes of the other allele, ranged 
from 1.19 to 1.49. The 2 SNPs most strongly associated with DVT were in 
CYP4V2 (rs13146272, P < .001, false discovery rate 0.0006) and SERPINC1 
(rs2227589, P < .001, false discovery rate, 0.004).
For the 2 SNPs on chromosome 1 (rs2227589 and rs670659), we investigated 
linkage disequilibrium with FVL. The SNP (rs2227589) in SERPINC1, which 
encodes antithrombin, is 4.37 megabases away from the FVL variant. The SNP 
in RGS7 (rs670659) is 71.48 megabases from FVL. Each was in weak linkage 
disequilibrium with FVL (r 2<.01). Restricting analyses to noncarriers of FVL 
did not appreciably change the risk estimate of either SNP (data not shown).
SNPs in CYP4V2 Region and DVT Risk 
The SNP with the strongest association with DVT was rs13146272, located 
in the gene encoding a member of the cytochrome P450 family 4 (CYP4V2). 
We genotyped 48 SNPs in this region in the LETS population (Table 4) and 
estimated the OR for DVT per copy of the risk-increasing allele. For many 
of the 48 SNPs, including rs13146272, the common allele was the risk allele. 
In LETS, rs13146272 had an OR for DVT of 1.22 (95% CI, 1.00-1.49). 
Higher ORs were observed for 9 of the other SNPs tested in this region. 
These SNPs were located in the CYP4V2, KLKB1 (coding for prekallikrein), 
and F11 (coding for coagulation factor XI) genes.
We then selected the 9 of the 48 SNPs that had an OR of more than 1.22 
(the OR of rs13146272) and investigated them in MEGA-1. We found 
that, in addition to rs13146272, four of these SNPs were associated with 
DVT in both LETS and MEGA-1: rs3087505, rs3756008, rs2036914, and 
rs4253418 (Table 5). The rs3087505 SNP in KLKB1 had the highest risk 
estimate: OR 3.61 (95% CI, 1.48-8.82) for the major allele homozygotes vs 
minor allele homozygotes. Mutual adjustment among these 5 SNPs did not 
indicate that any of these 5 associations were explained by the other 4 SNPs 
(data not shown).
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       Risk allele (%)
 
 
 
rs number Geneb SNP Typec Case Control OR
(95% CI)d
P
rs3822056 F11 5’near gene 90 89 1.07 (0.79 - 1.46) 0.65
rs3733403 F11 5’near gene 90 89 1.10 (0.81 - 1.50) 0.53
rs2036914 F11 intronic 60 54 1.25 (1.04 - 1.51) 0.02
rs4253408 F11 intronic 10 7 1.43 (1.01 - 2.01) 0.04
rs1593 F11 intronic 90 88 1.16 (0.85 - 1.57) 0.36
rs4253414 F11 intronic 3 3 1.07 (0.61 - 1.87) 0.82
rs4253418 F11 intronic 96 95 1.42 (0.88 - 2.27) 0.15
rs5974 F11 Thr267Thr 87 86 1.01 (0.77 - 1.32) 0.93
rs4253423 F11 intronic 85 83 1.13 (0.88 - 1.46) 0.33
rs5971 F11 Arg604Arg 96 96 1.01 (0.64 - 1.59) 0.97
rs4253430 F11 3’near gene 67 65 1.13 (0.92 - 1.37) 0.24
rs11938564 - intergenic 81 79 1.14 (0.91 - 1.43) 0.27
rs13136269 - intergenic 76 73 1.18 (0.95 - 1.46) 0.13
rs10025152 - intergenic 85 85 1.01 (0.78 - 1.32) 0.93
rs12500826 - intergenic 67 64 1.12 (0.93 - 1.36) 0.24
rs13133050 - intergenic 71 68 1.13 (0.93 - 1.38) 0.22
a  Gene symbols, rs numbers, SNP types, and chromosome numbers are from National Center 
for Biotechnology Information build 36.
b Some SNPs were located between genes, indicated in the “SNP type” column as “intergenic.”
c The ﬁrst amino acid corresponds to the nonrisk allele.
d Odds ratios were estimated by logistic regression using an additive model.
SNPs in CYP4V2 Region and Factor XI Levels
Because the F11 gene is located close to rs13146272 and because factor 
XI levels have been previously reported to be associated with DVT in the 
LETS population 171, we investigated whether an association between SNPs 
and factor XI levels explained the association between the SNPs and DVT. 
In LETS, factor XI levels above the 90th percentile had been shown to be 
associated with a 2-fold increased risk of DVT 171. We found that high factor 
XI levels (>90th percentile) were also associated with DVT in MEGA (OR, 
1.9; 95% CI, 1.6-2.3). 
The 5 SNPs from the CYP4V2 region that were associated with DVT were 
all associated with factor XI levels in LETS and MEGA-1, with higher 
factor XI levels for those who carried the risk-increasing alleles (Table 5). We 
investigated whether factor XI levels mediate the association between these 5 
SNPs and DVT by adjusting for factor XI levels in the combined LETS and 
MEGA-1 studies. For all 5 SNPs, adjustment for factor XI levels weakened the 
association with DVT but none of the associations disappeared. Interestingly, 
the 5 SNPs that were not associated with DVT in the combined analysis of 
LETS and MEGA-1 (rs3736456, rs4253259, rs4253408, rs4253325, and 
rs3775302) were also not associated with factor XI levels in LETS.
All analyses were performed with and without adjustment for age and sex, 
and analyses in MEGA-1 and MEGA-2 were performed with and without 
restriction to the group with both parents born in northwestern Europe. 
Because neither inﬂuenced the results, we presented the unadjusted OR. 
COMMENT 
We identiﬁed 7 SNPs that were associated with DVT in 3 large, well-
characterized populations including 3155 cases and 5087 controls. The 
evidence was strongest for the 3 SNPs in the CYP4V2, SERPINC1, and GP6 
genes. It is interesting to note that these SNPs are in or near genes that have a 
clear role in blood coagulation. This may indicate that the coagulation system 
is well characterized. 
Testing 19 682 SNPs will result in false-positive associations. Therefore, we 
investigated the SNPs in 3 large studies and estimated the false discovery rate for 
the SNPs tested in the third study. The 3 SNPs in genes CYP4V2, SERPINC1, 
and GP6 were associated with DVT with a false discovery rate of less than 
10%, which means that less than 10% of these 3 SNPs would be expected to 
be false positive. Relaxing the false discovery rate to less than 20% would add 4 
SNPs, in RGS7, NR1I2, NAT8B, and F9 as associated with DVT.
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   Risk allele, No. (%) Factor XIa Deep Vein Thrombosis
SNP Gene Risk 
Allele
Genotype Case Control % Diﬀerence 
(95% CI)
OR (95% CI) OR b (95% CI)
rs2036914 F11 C TT 302 (17) 505 (23) [Reference] 1 [Reference] 1 [Reference]
  TC 895 (49) 1081 (49) 7 (5 to 9) 1.38 (1.17 to 1.64) 1.27 (1.07 to 1.51)
  CC 633 (35) 620 (28) 14 (12 to 16) 1.71 (1.43 to 2.05) 1.43 (1.19 to 1.73)
  Additive (59) (53) 7 (6 to 8) 1.30 (1.19 to 1.42) 1.19 (1.08 to 1.30)
rs4253418 F11 G AA 3 (0) 4 (0) [Reference] 1 [Reference] 1 [Reference]
  AG 120 (7) 199 (9) 14 (10 to 19) 0.80 (0.18 to 3.65) 0.69 (0.15 to 3.14)
  GG 1710 (93) 2000 (91) 22 (18 to 26) 1.14 (0.26 to 5.10) 0.88 (0.20 to 3.94)
  Additive (97) (95) 8 (5 to 11) 1.39 (1.11 to 1.74) 1.24 (0.99 to 1.56)
Table 5. Association of 10 SNPs in CYP4V2 Region With Deep Vein Thrombosis and Factor XI 
Levels in the Combined LETS and MEGA-1 Studies.
   Risk allele, No. (%) Factor XIa Deep Vein Thrombosis
SNP Gene Risk 
Allele
Genotype Case Control % Diﬀerence 
(95% CI)
OR (95% CI) OR b (95% CI)
rs13146272 CYP4V2 A CC 181 (10) 296 (13) [Reference] 1 [Reference] 1 [Reference]
  CA 808 (44) 995 (45) 3 (1 to 6) 1.32 (1.07 to 1.62) 1.26 (1.03 to 1.56)
  AA 850 (46) 919 (42) 7 (4 to 9) 1.50 (1.22 to 1.84) 1.36 (1.10 to 1.68)
  Additive (68) (64) 3 (2 to 4) 1.20 (1.09 to 1.31) 1.14(1.04 to 1.25)
rs3736456 CYP4V2 T CC 7 (0) 0 (0)  
  CT 163 (9) 222 (10) [Reference] 1 [Reference] 1 [Reference]
  TT 1663 (91) 1973 (90) 1 (-1 to 4) 1.16 (0.93 to 1.43) 1.15 (0.93 to 1.42)
  Additive (95) (95) 1 (-2 to 4) 1.06 (0.86 to 1.30) 1.05 (0.85 to 1.28)
rs3087505 KLKB1 C TT 6 (0) 25 (1) [Reference] 1 [Reference] 1 [Reference]
  TC 317 (17) 438 (20) 11 (6 to 16) 3.02 (1.22 to 7.44) 2.59 (1.05 to 6.40)
  CC 1509 (82) 1743 (79) 19 (14 to 24) 3.61 (1.48 to 8.82) 2.81 (1.15 to 6.89)
  Additive (91) (89) 8 (6 to 10) 1.27 (1.09 to 1.47) 1.15 (0.99 to 1.34)
rs4253259 KLKB1 C AA 5 (0) 6 (0) [Reference] 1 [Reference] 1 [Reference]
  AC 168 (9) 219 (10) 0 (-18 to 18) 0.92 (0.28 to 3.07) 0.95 (0.28 to 3.20)
  CC 1652 (91) 1978 (90) 0 (-19 to 18) 1.00 (0.31 to 3.29) 1.03 (0.31 to 3.43)
  Additive (95) (95) 0 (-3 to 2) 1.08 (0.88 to 1.32) 1.08 (0.88 to 1.32)
rs4253408 F11 A GG 1526 (83) 1869 (85) [Reference] 1 [Reference] 1 [Reference]
  GA 293 (16) 317 (14) 4 (2 to 6) 1.13 (0.95 to 1.35) 1.06 (0.89 to 1.27)
  AA 15 (2) 17 (1) 13 (-1 to 27) 1.08 (0.54 to 2.17) 0.97 (0.48 to 1.98)
  Additive (9) (8) 5 (3 to 7) 1.11 (0.95 to 1.30) 1.05 (0.89 to 1.23)
rs4253325 F11 G AA 21 (1) 23 (1) [Reference] 1 [Reference] 1 [Reference]
  AG 308 (17) 392 (18) 5 (0 to 16) 0.86 (0.47 to 1.58) 0.86 (0.46 to 1.59)
  GG 1507 (82) 1785 (81) 8 (-3 to 13) 0.93 (0.51 to 1.68) 0.88 (0.48 to 1.62)
  Additive (90) (90) 3 (1 to 5) 1.05 (0.91 to 1.21) 1.01 (0.87 to 1.17)
rs3775302 KLKB1 A GG 1418 (77) 1686 (77) [Reference] 1 [Reference] 1 [Reference]
  GA 380 (21) 481 (22) -1 (-3 to 1) 0.94 (0.81 to 1.09) 0.97 (0.83 to 1.13)
  AA 38 (2) 34 (2) -4 (-11 to 3) 1.33 (0.83 to 2.12) 1.34 (0.83 to 2.14)
  Additive (12) (12) -1 (-3 to 0) 1.00 (0.87 to 1.14) 1.02 (0.89 to 1.16)
rs3756008 F11 T AA 526 (29) 788 (36) [Reference] 1 [Reference] 1 [Reference]
  AT 903 (49) 1032 (47) 7 (6 to 9) 1.31 (1.14 to 1.51) 1.21 (1.04 to 1.39)
  TT 408 (22) 384 (17) 15 (12-17) 1.59 (1.33 to 1.90) 1.32 (1.09 to 1.59)
  Additive (47) (41) 7 (6 to 8) 1.27 (1.16 to 1.38) 1.16 (1.05 to 1.27)
The 3 SNPs with the strongest evidence for association with DVT were in the 
genes CYP4V2, SERPINC1, and GP6. The CYP4V2 gene encodes a member 
of the CYP450 family 4 that is not known to be related to thrombosis 174,175. 
The CYP4V2 gene is located on chromosome 4 in a region containing genes 
encoding coagulation proteins prekallikrein (KLKB1) and factor XI (F11). 
We also found 4 other SNPs in the CYPV42/KLKB1/F11 locus that were 
associated with DVT. No previous reports exist of genetic variants in CYP4V2 
and KLKB1 and their association with DVT. There exists no evidence for an 
association between prekallikrein levels and DVT 176, while there is evidence 
for elevated factor XI levels 160,171. It remains unclear whether only one of 
these SNPs, or all of them affect DVT risk.
The SERPINC1 gene encodes antithrombin, a serine protease inhibitor 
located on chromosome 1 that plays a central role in natural anticoagulation. 
Deﬁciencies of antithrombin are rare but result in a strong thrombotic tendency 
177. The SNP in SERPINC1 (rs2227589) had a minor allele frequency of about 
10% in the controls and was associated with a modest thrombotic tendency. The 
GP6 gene encodes glycoprotein VI, a 58-kDa platelet membrane glycoprotein 
that plays a crucial role in the collagen-induced activation and aggregation of 
platelets 178 and may play a role in DVT 179.
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The SNPs in the genes F9, NR1I2, RGS7, and NAT8B are of interest for further 
validation. The F9 gene encodes factor IX, a vitamin K–dependent coagulation 
factor, of which high levels have been shown to increase the risk of DVT 180. 
The SNP rs6048, also known as F9 Malmö, is a common polymorphism at the 
third amino acid residue of the activation peptide of factor IX 181.
The SNP in CYP4V2 (rs13146272) is located close to the gene encoding 
coagulation factor XI. Factor XI levels have been reported to be associated 
with DVT in LETS 171 and in a large analysis of pedigrees 160. We conﬁrmed 
the association between DVT and factor XI levels in MEGA. Interestingly, 
the 5 SNPs in the CYP4V2 region that were associated with DVT in both 
LETS and MEGA-1 were also associated with factor XI levels. However, the 
association between these 5 SNPs and DVT does not seem to be completely 
explained by variation in factor XI levels because adjusting for factor XI level 
did not remove the excess DVT risk of these 5 SNPs. Thus, if only part of the 
risk associated with these genetic variants is mediated through levels of factor 
XI, some of the risk might also be due to effects on protein function. 
Several variants in the F11 gene (rs5974, rs5970, rs5971, rs5966, rs5976, 
and rs5973) were previously tested for association with factor XI levels in 
patients with DVT and atherosclerosis, but no relationship was observed 182. 
In the present study, rs5974 (r 2 = 1.0 with 5970) and rs5971 (r 2 = 1.0 with 
5966 and rs5976) were not associated with DVT in LETS. Rs5973 was not 
genotyped because its minor allele frequency was lower than 2% (HapMap 
CEPH population). In a study of West African volunteers 129, rs3822056 
and rs3733403 were associated with transcription factor binding afﬁnity and 
slightly increased factor XI levels, but neither SNP was associated with DVT 
in LETS. In a study among white postmenopausal women 183, rs3822057 
and rs2289252 were associated with DVT. Both of these associations were 
indirectly conﬁrmed in the present study because 2 of the 5 SNPs in the 
CYPV42 region that were consistently associated with DVT and factor XI 
levels are in linkage disequilibrium with rs3822057 (r 2 = 0.9 with rs2036914) 
and rs2289252 (r 2 = 0.8 with rs3756008). 
The association between genetic variants and DVT may depend on clinical 
variables or other risk factors for DVT, such as surgery or the use of oral 
contraceptives. Because we aimed to identify variants that are associated with 
DVT in general and from a large set of SNPs, we did not study subgroups. 
Clinical utility, however, may well depend on interaction with these clinical 
variables and should form a focus of subsequent studies. 
The associations between SNPs and DVT were modest, for instance 
homozygous carriership of the AA genotype of rs13146272 in CYP4V2 
increased risk 1.49-fold. However, because the variants are common, they 
might be useful risk indicators especially when combined with other risk 
factors. Moreover, the associations found might represent a diluted effect 
of an unmeasured SNP in linkage disequilibrium or indicate a region with 
several variants involved in DVT susceptibility. The results from the CYP4V2 
region illustrate the need for further study, because some ORs found in that 
region were higher than initially found for rs13146272. 
Only 9 of 18 stage 3 SNPs were indeed tested in MEGA-2 DNA in stage 4. 
The reason for this was that in order to save MEGA-2 DNA, stage 4 SNPs 
were genotyped using multiplexed oligoligation assays, and assays for only 
9 stage 3 SNPs were available at the time of this study. Therefore, a future 
extension of this study may yield additional SNPs associated with DVT. 
The replication criteria that we used to identify SNPs associated with DVT 
may have caused us to miss some truly associated positive variants. Although 
the statistical power to detect associations between DVT and uncommon 
genetic variation was high, a rare variant with a modest association with 
DVT may have been missed. 
Our analysis was limited to a northwestern European population. 
Confounding in a genetic study may arise from population stratiﬁcation, 
ie, the presence of ethnic groups with different allele and disease frequencies 
within a study. In LETS, no information on ethnicity was collected. However, 
